

A vertical strip on the left side of the cover features a microscopic image of placental tissue, showing various cellular structures and blood vessels in shades of orange and red.

# WHO guidelines for the management of postpartum haemorrhage and retained placenta



# WHO guidelines for the management of postpartum haemorrhage and retained placenta

WHO Library Cataloguing-in-Publication Data:

**WHO guidelines for the management of postpartum haemorrhage and retained placenta.**

1.Placenta, Retained - therapy. 2.Postpartum hemorrhage - diagnosis. 3.Postpartum hemorrhage - therapy. 4.Obstetric labor complications. 5.Guidelines. I.World Health Organization.

ISBN 978 92 4 159851 4

(NLM classification: WQ 330)

**© World Health Organization 2009**

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France.

# Contents

<b>Background</b>	<b>1</b>
<b>Methods</b>	<b>2</b>
<b>Scope of the guidelines</b>	<b>3</b>
<b>Evidence and recommendations</b>	<b>4</b>
<b>A. Diagnosis of PPH</b>	<b>4</b>
1. Should blood loss be routinely quantified during management of the third stage of labour for the purpose of diagnosing PPH?	4
<b>B. Management of atonic PPH</b>	<b>5</b>
1. Medical interventions for management of PPH	5
2. Non-medical interventions for management of PPH	12
3. Surgical interventions in the treatment of PPH	16
<b>C. Management of retained placenta</b>	<b>17</b>
1. Should uterotonics be offered as treatment for retained placenta?	17
2. Should intra-umbilical vein injection of oxytocin with or without saline be offered as treatment for retained placenta?	18
3. Should antibiotics be offered after manual extraction of the placenta as part of the treatment of retained placenta?	19
<b>D. Choice of fluid for replacement or resuscitation</b>	<b>20</b>
1. Should crystalloids be offered for fluid replacement in women with PPH?	20
<b>E. Health systems and organizational interventions</b>	<b>21</b>
1. Should health care facilities have a protocol for management of PPH?	21
2. Should health care facilities have a formal protocol for referral of women diagnosed as having PPH?	21
3. Should simulation of PPH treatment be part of training programmes for health care providers?	22
<b>PPH care pathways</b>	<b>22</b>
<b>Research Implications</b>	<b>24</b>
<b>Plans for local adaptation of the recommendations</b>	<b>26</b>
<b>Plans for supporting implementation of these recommendations</b>	<b>26</b>
<b>GRADE tables</b>	<b>26</b>
A. Diagnosis of PPH	27
B. Management of atonic PPH	28
C. Management of retained placenta	33
D. Choice of fluid for replacement or resuscitation	38
<b>References</b>	<b>40</b>
<b>Annex 1.</b> Scoping document with average scores	47
<b>Annex 2.</b> Search strategy	50
<b>Annex 3.</b> GRADE methodology	51
<b>Annex 4.</b> List of participants	54

## Acknowledgements

This document was prepared by Dr A. Metin Gülmezoglu, Dr João Paulo Souza and Dr Doris Chou (WHO Department of Reproductive Health and Research), Dr Matthews Mathai (WHO Department of Making Pregnancy Safer), Dr Suzanne Hill (WHO Essential Medicines and Pharmaceutical Policies) and Dr Edgardo Abalos (Centro Rosarino de Estudios Perinatales, Rosario, Argentina), on the basis of discussions at the WHO Technical Consultation on the Management of Postpartum Haemorrhage and Retained Placenta, held in Geneva on 18-21 November 2008. The document was finalized after consideration of all comments and suggestions from the participants of the Consultation to earlier drafts and an internal WHO review.

WHO gratefully acknowledges the contributions of the Chair of the Consultation (Dr Pisake Lumbiganon) and of the international panel of experts who provided input to the Consultation. The assistance of Centro Rosarino de Estudios Perinatales, Rosario, Argentina, and of Ms Mary Ellen Stanton are also gratefully acknowledged.

The process leading to the preparation of these guidelines was financially supported by the WHO Department of Reproductive Health and Research and the United States Agency for International Development (USAID).

WHO Secretariat will review the questions below in the update of this guideline planned for 2010-2011.

## Declarations of interest

Six temporary advisors (Hany Abdel-Aleem, Jennifer Blum, Richard Derman, Justus Hofmeyr, Pisake Lumbiganon and Tran Son Thach) and one observer (Beverly Winikoff) declared that they had received grants for conducting research and made presentations on the research they conducted regarding the use of misoprostol and other aspects of PPH prevention and management which were reviewed during the meeting. None of these grants was from commercial entities. One observer, Ms Mary Ellen Stanton, declared that she may present an organization's position (USAID) if required in this field.

The interests declared reflect the academic interest and opinions of the experts and the Secretariat does not believe that there are any undeclared commercial or financial interests among the guideline review group.

The two observers did not participate in the voting processes and were not asked to approve or provide comments to the document.

## ► Background

One of the Millennium Development Goals set by the United Nations in 2000 is to reduce maternal mortality by three-quarters by 2015. If this is to be achieved, maternal deaths related to postpartum haemorrhage (PPH) must be significantly reduced. In support of this, health workers in developing countries need to have access to appropriate medications and to be trained in relevant procedures. But beyond this, countries need evidence-based guidelines on the safety, quality, and usefulness of the various interventions. These will provide the foundation for the strategic policy and programme development needed to ensure realistic and sustainable implementation of appropriate interventions.

PPH is generally defined as blood loss greater than or equal to 500 ml within 24 hours after birth, while severe PPH is blood loss greater than or equal to 1000 ml within 24 hours. PPH is the most common cause of maternal death worldwide. Most cases of morbidity and mortality due to PPH occur in the first 24 hours following delivery and these are regarded as primary PPH whereas any abnormal or excessive bleeding from the birth canal occurring between 24 hours and 12 weeks postnatally is regarded as secondary PPH.

PPH may result from failure of the uterus to contract adequately (atony), genital tract trauma (i.e. vaginal or cervical lacerations), uterine rupture, retained placental tissue, or maternal bleeding disorders. Uterine atony is the most common cause and consequently the leading cause of maternal mortality worldwide.

In practice, blood loss after delivery is seldom measured and it is not clear whether measuring blood loss improves the care and outcome for the women. In addition, some women may require interventions to manage PPH with less blood loss than others if they are anaemic.

Risk factors for PPH include grand multiparity and multiple gestation. However, PPH may occur in women without identifiable clinical or historical risk factors. It is therefore recommended that active management of the third stage of labour be offered to all women during childbirth, whenever a skilled provider is assisting with the delivery (1). Active management should include: (i) administration of a uterotonic soon after the birth of the baby; (ii) clamping of the cord following the observation of uterine contraction (at around 3 minutes); and (iii) delivery of the placenta by controlled cord traction, followed by uterine massage.

Even with these efforts to prevent PPH, some women will still require treatment for excessive bleeding. Multiple interventions (medical, mechanical, invasive non-surgical and surgical procedures), requiring different levels of skill and technical expertise, may be attempted to control bleeding. For the purposes of these guidelines, it is assumed that the patient with PPH is being treated by a health-care worker in a medical facility. Efforts in the community to prevent and treat PPH are not covered here.

Effective treatment of PPH often requires simultaneous multidisciplinary interventions. The health care provider needs to begin resuscitative efforts quickly,

establish the cause of the haemorrhage, and possibly obtain the assistance of other care providers, such as an obstetrician, anaesthetist or radiologist. Avoiding delays in diagnosis and treatment will have a significant impact on sequelae and chance of survival. These guidelines therefore include “care pathways” (or algorithms) for management of PPH, as a practical guide for clinicians. (A loose-leaf insert of these care pathways has been included for use as a wall chart.)

This document is not intended to be a comprehensive guide on management of PPH and retained placenta. Rather, it reflects the questions that were regarded as high priority by a multidisciplinary panel of international health workers and consumers.

## ► Methods

Staff from the WHO Departments of Reproductive Health and Research, Making Pregnancy Safer, and Essential Medicines and Pharmaceutical Policies drafted questions on interventions and a list of possible outcomes in the treatment of atonic postpartum haemorrhage and retained placenta (Annex 1).

These questions and outcomes were sent by email to an international panel of experts (midwives, obstetricians, neonatologists, researchers, methodologists, consumers and programme experts). Members of the panel were invited to comment on the relevance of the questions and outcomes, and were asked to rate each of them on a scale of 1 to 9. A critical outcome was defined as an outcome with an average score between 7 and 9. Questions and outcomes that scored between 4 and 6 were considered important but not critical, while those that scored less than 4 were considered not important (2). Panel members were also encouraged to revise the questions or suggest new questions and outcomes.

Two reminders were sent to the members of the panel. The results of the scoping exercise were sent to all respondents for review. All of the responses were reviewed by WHO staff. The responses and scores are presented in Annex 1. In the preparation of the care pathways for management of PPH and retained placenta, questions that scored lower than critical points in the scoping exercise were included in the search for evidence and appraisal process.

Centro Rosarino de Estudios Perinatales (CREP), a WHO Collaborating Centre in Maternal and Perinatal Health, was commissioned to search, review and grade the evidence to answer the questions, using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology (Annex 3). The initial search for evidence was conducted in November 2007. Records were searched in the Cochrane library, Pubmed, Embase, and Lilacs. The search terms used are given in Annex 2. Ad hoc searches in Pubmed were also conducted before the Technical Consultation to make sure that relevant studies were not missed and that studies identified by experts in the field were included.

GRADE tables were prepared for the highest level of evidence available; systematic reviews and randomized controlled trials (RCTs) or, in their absence, observational studies were used. When RCTs were available, observational study data were not

summarized in the GRADE tables. However, they were mentioned in the evidence summary and taken into account in the recommendation. GRADE tables were not prepared for case series or reports.

The draft GRADE tables were reviewed by the WHO Secretariat together with CREP staff. Recommendations relating to the questions and outcomes proposed were then drafted ahead of the Technical Consultation. A draft of the methodology, results, and recommendations was sent for review to a subgroup of the experts participating in the Technical Consultation before the meeting.

### Decision-making during the technical consultation

For each question, the participants in the Technical Consultation discussed the draft text prepared by the Secretariat, with the aim of reaching a consensus. Consensus was defined as agreement by the majority of participants, provided that those who disagreed did not feel strongly about their position. Any strong disagreements were recorded as such.

During the meeting, in addition to the documentation prepared by the Secretariat, preliminary results from four unpublished trials were made available. While the presentation of the most recent data from large trials was welcomed and used to inform the recommendations, some participants expressed a need for more time to review these results before making recommendations. The GRADE tables in this document include evidence from the search as well as the data presented and discussed during the Technical Consultation.

The system used to establish the strength and ranking of the recommendations involved assessing each intervention on the basis of: (i) desirable and undesirable effects; (ii) quality of available evidence; (iii) values and preferences related to interventions in different settings; and (iv) cost of options available to health care workers in different settings.

## ► Scope of the guidelines

The draft questions and list of outcomes related to the treatment of PPH and management of retained placenta were sent to 144 experts from all parts of the world. Responses were received from 60 of these experts: 46 physicians, 7 midwives, and 7 non-clinicians (policy-makers, researchers and consumers), representing all 6 WHO regions.

There were 39 questions in 6 domains:

- assessment of blood loss (1 question);
- drugs for atonic PPH (13 questions);
- non-drug interventions for atonic PPH:
  - mechanical (6 questions);
  - radiological (1 question);
  - surgical (8 questions);

- retained placenta (4 questions);
- organizational and educational interventions (5 questions);
- crystalloid versus colloid fluids for resuscitation (1 question). This question was included following a suggestion from the respondents during the survey.

The average scores for questions and outcomes are shown in Annex 1.

It should be noted that not all outcomes are applicable to all questions. As mentioned above, questions that scored less than 7 are also included in the guidelines.

## ► Evidence and recommendations

### A. Diagnosis of PPH

#### 1. Should blood loss be routinely quantified during management of the third stage of labour for the purpose of diagnosing PPH?

Several related studies that looked at measurement of blood loss following childbirth, with the objective of ensuring timely diagnosis of PPH and improving health outcomes, were assessed. No study was found that directly addressed the question.

##### Summary of evidence

##### *Visual versus quantitative methods for estimating blood loss after vaginal delivery*

One RCT (3) compared visual estimation of blood loss with measurement of blood collected in a plastic drape. Six observational studies (4-9), with a total of 594 participants, compared visual estimation with known values in the delivery room or in simulated scenarios. Three studies (10-12) compared visual or quantified estimations with laboratory measurement in 331 vaginal deliveries.

In the RCT (3), visual estimation underestimated blood loss when compared with drape measurement (mean difference 99.71 ml) (page 27, [GRADE Table A1](#)). Visual methods underestimated blood loss when compared with known simulated volumes.

##### *Training courses on estimating blood loss after vaginal delivery*

One RCT (13) compared the accuracy of estimation of blood loss by 45 nurses attending a course on blood loss estimation and 45 nurses not attending the course. In this small RCT (13), with seven simulated scenarios, blood loss was accurately estimated by 75.55% of the nurses attending a training course compared with 24.44% without training (relative risk (RR) 3.09; 95% confidence interval (CI) 1.80-5.30) (page 27, [GRADE Table A2](#)).

In three studies (14-16), a total of 486 staff members of maternity services visually estimated blood loss in simulated scenarios before and after training courses. The three uncontrolled studies (14-16) show results in the same direction as the RCT.

### Recommendation

After childbirth, blood loss and other clinical parameters should be closely monitored. At present, there is insufficient evidence to recommend quantification of blood loss over clinical estimation. (Quality of evidence: low. Strength of recommendation: strong)

### Remarks

The participants identified several priority research topics related to the definition and diagnosis of PPH.

- What quantity of blood loss should be the marker for diagnosis of PPH?
- Does the act of quantifying blood loss alter (or lead to improved) clinical outcomes for the mother and her baby?
- Which clinical consequences of blood loss are of greatest value for the diagnosis and treatment of PPH?

## B. Management of atonic PPH

As a general preventive approach, the use of oxytocin for active management of the third stage of labour is strongly recommended, because it reduces PPH by more than 60% (17).

### 1. Medical interventions for management of PPH

The Consultation was asked to assess the value of injectable uterotonics (oxytocin, ergometrine, fixed dose combination of oxytocin and ergometrine, carbetocin and injectable prostaglandin), misoprostol (tablet form used via oral, sublingual and rectal routes), injectable tranexamic acid and injectable recombinant factor VIIa in the management of PPH thought to be due to uterine atony.

For oxytocin, ergometrine and prostaglandin F<sub>2α</sub>, the Consultation agreed with the doses recommended in the WHO guide, *Managing complications in pregnancy and childbirth* (18), as given in Table 1 (overleaf).

The recommendations below may also be used in cases of PPH due to uterine atony following caesarean section. The Consultation acknowledged that these recommendations were based primarily on data following vaginal birth, and that specific data on PPH due to uterine atony following caesarean section were scarce and not evaluated separately from data on vaginal births.

#### **(a) Which uterotonics should be offered in the management of PPH due to uterine atony?**

##### Summary of evidence

Except for the specific misoprostol trials evaluated in section (b), the evidence has been extrapolated from research on prevention of PPH. Systematic reviews comparing the effects of oxytocin with ergometrine (19), a fixed-dose combination

of oxytocin and ergometrine (20), carbetocin (21) and prostaglandins (22) in the prevention of PPH were reviewed. The guidelines on prevention of postpartum haemorrhage published by WHO synthesized and graded the evidence and made recommendations (1). That publication includes the relevant GRADE tables.

Separate GRADE tables were not prepared for this question and the evidence is summarized below narratively. One RCT comparing oxytocin to ergometrine in 600 women (23) was published subsequent to the systematic review and publication of the WHO guidelines.

**Table 1.** Drug doses for management of PPH

	Oxytocin	Ergometrine/ Methyl-ergometrine	15-Methyl prostaglandin F2a
Dose and route	IV: Infuse 20 units in 1 l IV fluids at 60 drops per minute	IM or IV (slowly): 0.2 mg	IM: 0.25 mg
Continuing dose	IV: Infuse 20 units in 1 l IV fluids at 40 drops per minute	Repeat 0.2 mg IM after 15 minutes  If required, give 0.2 mg IM or IV (slowly every 4 hours	0.25 mg every 15 minutes
Maximum dose	Not more than 3 l of IV fluids containing oxytocin	5 doses (Total 1.0 mg)	8 doses (Total 2 mg)
Precautions/ contraindications	Do not give as an IV bolus	Pre-eclampsia, hypertension, heart disease	Asthma

Prostaglandin F2a should not be given intravenously. It may be fatal. *Managing complications in pregnancy and childbirth*. Geneva, World Health Organization, 2000, page S-28, table S-8.

IV intravenous  
IM intramuscular

### *Oxytocin vs ergometrine*

One trial (24) included in the systematic review reported on the critical outcomes of blood loss of  $\geq 1000$  ml and need for blood transfusion. There was no difference in incidence of blood loss  $\geq 1000$  ml (RR 1.09, 95%CI 0.45-2.66). Blood transfusion was given to 2 of 78 women receiving oxytocin compared with 1 of 146 women receiving ergometrine (RR 3.74, 95%CI 0.34-40.64). No significant difference was observed in the use of additional uterotonics in two trials in the systematic review (24, 25): in 35 of 557 women given oxytocin and 46 of 651 women given ergometrine (RR 1.02, 95% CI 0.67-1.55).

In the later Nigerian trial (23), the use of additional uterotonics was reported in 18 of 297 patients receiving oxytocin in the third stage of labour compared with 30 of 303 receiving ergometrine (RR 0.61, 95%CI 0.35-1.07). The incidence of adverse side-effects was significantly lower in women receiving oxytocin than in those given ergometrine; for vomiting, the RR was 0.09 and the 95% CI 0.05-0.16); for elevated blood pressure, RR was 0.01 and 95% CI 0.00-0.15).

*Oxytocin-ergometrine fixed dose combination vs oxytocin*

With regard to blood loss  $\geq 1000$  ml, decreased blood loss was observed in the group given the fixed-dose combination of oxytocin (5 IU) and ergometrine (0.5 mg) although the difference was not statistically significant (Peto odds ratio (OR) 0.78, 95%CI 0.58-1.03). In four studies that reported on the use of blood transfusion, there was no significant difference and wide confidence interval compatible with either direction of effect (Peto OR 1.37, 95%CI 0.89-2.10). Three studies reported a slight, but statistically significant, lower use of additional uterotonics in the group receiving fixed dose oxytocin-ergometrine combination (RR 0.83, 95%CI 0.72-0.96). Four studies reported on the incidence of side-effects, notably a higher incidence of elevated diastolic blood pressure in the group given the oxytocin-ergometrine fixed dose combination (RR 2.40, 95%CI 1.58-3.64).

*Oxytocin-ergometrine fixed dose combination vs ergometrine*

None of the critical outcomes was addressed in the studies.

*Carbetocin vs oxytocin*

No data on blood loss  $\geq 1000$  ml, blood transfusion or surgical treatments were available. For the other priority outcomes, the use of additional uterotonics was similar in the two groups (RR 0.93, 95%CI 0.44-1.94), but there was less use of uterine massage in the carbetocin group (RR 0.70, 95% CI 0.51-0.94). Data on side-effects were too limited to allow any judgements to be made (nausea: RR 0.66, 95%CI 0.22-2.00; vomiting: RR 0.07, 95%CI 0.00-1.25; headache: RR 0.51, 95%CI 0.20-1.30).

*Carbetocin vs Oxytocin-ergometrine fixed dose combination*

Of 150 women given carbetocin and 150 given oxytocin-ergometrine fixed dose combination, only one woman given the combination experienced blood loss  $\geq 1000$  ml (26). Use of additional uterotonics was similar, with wide confidence intervals (RR 1.3, 95%CI 0.56-3.13), but the occurrence of side-effects was lower in the carbetocin group (nausea: RR 0.18, 95%CI 0.04-0.78; hypertension up to 60 minutes postpartum: RR 0.11, 95%CI 0.03-0.47). In a smaller observational study (27), fewer women in the carbetocin group had a blood loss of  $>1000$  ml (1 of 55 given carbetocin and 9 of 62 given the combination (RR 0.12, 95%CI 0.15-0.94)).

*Intramuscular prostaglandins vs injectable uterotonics*

No difference was observed in the risk of blood transfusion between these two treatments (RR 1.05, 95%CI 0.39-2.86). Use of additional uterotonics was not significantly different between the prostaglandin group (4 of 106) and the injectable uterotonic group (2 of 116) (RR 2.05, 95%CI 0.39-10.92). Vomiting was observed in 15 of 103 patients receiving prostaglandin and 1 of 107 patients receiving injectable uterotonics (RR 10.74, 95%CI 2.06-56.02).

*Sulprostone vs injectable uterotonics*

Two RCTs conducted in the Netherlands (28, 29) reported on estimated blood loss of  $\geq 1000$  ml. There was a nonsignificant reduction in the risk of severe PPH in both

low-risk (28) and high-risk women (29) (RR 0.41, 95%CI 0.14-1.20) in women receiving sulprostone. The Van Selm study (29) was terminated early because of concerns regarding myocardial infarctions in women treated with sulprostone and mifepristone.

#### *Carboprost vs misoprostol*

No evidence was found relating to the priority outcomes regarding blood loss. Of 60 patients in the carboprost group, none received a blood transfusion compared with 1 of 60 in the misoprostol group (RR 0.33, 95%CI 0.01-8.02) (30). No patients in the carboprost group reported shivering, compared with 5 in the misoprostol group (RR 0.09, 95%CI 0.01-1.61).

#### *Misoprostol vs injectable uterotonics*

When compared with injectable uterotonics there was an increase in the risk of blood loss of  $\geq 1000$  ml in women receiving oral misoprostol (400-800  $\mu\text{g}$ ) (RR 1.32, 95%CI 1.16-1.51), but no statistically significant difference in the incidence of severe morbidity, including maternal death (RR 1.00, 95%CI 0.14-7.10). These trials did not report the outcome of invasive or surgical treatments.

### Recommendations

- For management of PPH, oxytocin should be preferred over ergometrine alone, a fixed-dose combination of ergometrine and oxytocin, carbetocin, and prostaglandins. (Quality of evidence: very low to low. Strength of recommendation: strong.)
- If oxytocin is not available, or if the bleeding does not respond to oxytocin, ergometrine or oxytocin-ergometrine fixed-dose combination should be offered as second-line treatment. (Quality of evidence: very low to low. Strength of recommendation: strong.)
- If the above second-line treatments are not available, or if the bleeding does not respond to the second-line treatment, a prostaglandin should be offered as the third line of treatment. (Quality of evidence: very low to low. Strength of recommendation: strong.)

### Remarks

- The above recommendations are based largely on data from prevention trials or case series. However, data from treatment RCTs were available for misoprostol versus oxytocin.
- The pharmacokinetics, bioavailability and mode of action of oxytocin and ergometrine and the uterotonic effects of misoprostol in other obstetric and gynaecological uses were considered by the participants in the Consultation in making the recommendations.
- Misoprostol may be considered as a third line of treatment for the management of PPH, because of its ease of administration and low cost compared with injectable prostaglandins (see also section (b)).

- The Consultation noted that the cost of carbetocin was high compared with the other options. Moreover, it found no evidence that carbetocin has a significant advantage over oxytocin.

### ***(b) Should misoprostol be offered in the management of PPH due to uterine atony?***

The Consultation made recommendations relating to two separate scenarios: women who received prophylactic oxytocin during the third stage of labour and those who did not.

#### **(i) Should misoprostol be offered for the management of PPH in women who have received prophylactic oxytocin during the third stage of labour?**

##### **Summary of evidence**

Four trials assessed the use of misoprostol as an adjunct following active management of the third stage of labour with oxytocin (31-34). The three published trials (31-33) were relatively small, with a total of 465 women participating. The unpublished WHO-Gynuity trial (34) included 1400 women in Argentina, Egypt, South Africa, Thailand and Viet Nam. In three trials (31, 33, 34), 600 µg of misoprostol was administered orally or sublingually, while in the fourth trial (32) 1000 µg was administered orally, sublingually or rectally. The results of the WHO-Gynuity trial (34) were presented to the Consultation and are included in the GRADE table (page 28, [GRADE Table B1](#)).

Taken altogether, when misoprostol as an adjunct was compared with placebo in women receiving other standard treatments, there were no statistical differences in the critical outcomes of additional blood loss  $\geq 500$  ml (RR 0.83, 95%CI 0.64-1.07), additional blood loss  $\geq 1000$  ml (RR 0.76, 95%CI 0.43-1.34) and blood transfusion (RR 0.96, 95%CI 0.77-1.19). Similarly, in the large WHO-Gynuity trial (34), the critical outcomes of additional blood loss  $\geq 500$  ml (RR 1.01, 95%CI 0.78-1.30), additional blood loss  $\geq 1000$  ml (RR 0.76, 95%CI 0.43-1.34) and blood transfusion (RR 0.89, 95%CI 0.69-1.13) were not clinically or statistically significantly different in the two groups.

##### **Recommendation**

There is no added benefit of offering misoprostol as adjunct treatment for PPH in women who have received oxytocin during the third stage of labour. Where oxytocin is available, and is used in the management of the third stage of labour, oxytocin alone should be used in preference to adjunct misoprostol for the management of PPH. (Quality of evidence: moderate to high. Strength of recommendation: strong.)

##### **Remark**

The recommendation is based mainly on data from one large unpublished randomized controlled trial (34).

#### **(ii) Should misoprostol be offered as a treatment for PPH in women who did not receive prophylactic oxytocin during the third stage of labour?**

### Summary of evidence

The evidence relating to this question came from one large RCT conducted in Ecuador, Egypt and Viet Nam (35), which compared 800 µg of misoprostol given sublingually with 40 IU of oxytocin given intravenously. Unpublished trial results were presented to the Consultation (page 29, [GRADE Table B2](#)). Women who received misoprostol had a significantly increased risk of additional blood loss  $\geq 500$  ml (RR 2.66, 95%CI 1.62-4.38) and of needing additional therapeutic uterotonics (RR 1.79, 95%CI 1.19-2.69). There were few cases of additional blood loss  $\geq 1000$  ml (5 of 488 in the group given misoprostol and 3 of 489 given oxytocin). There was an increased risk of blood transfusion in the misoprostol group, of borderline statistical significance (RR 1.54, 95%CI 0.97-2.44).

Regarding side-effects, 66 of 488 women receiving misoprostol had a body temperature above 40 °C, compared with none of 490 given oxytocin. Most of the cases of high temperature occurred in Ecuador, where 36% of the women given misoprostol had a temperature above 40 °C. There were no cases in Egypt. Seven of the women with high temperature had delirium.<sup>1</sup>

### Recommendation

In women who have not received oxytocin as a prophylactic during the third stage of labour, oxytocin alone should be offered as the drug of choice for the treatment of PPH. (Quality of evidence: moderate to high. Strength of recommendation: strong.)

### Remarks

- Evidence of the superiority of oxytocin over misoprostol for the treatment of PPH came from one large trial, which showed oxytocin to have higher effectiveness and fewer side-effects.
- The Consultation recognized that oxytocin may not be available in all settings. It encouraged health care decision-makers in these settings to strive to make oxytocin and other injectable uterotonics available. However, because the use of a uterotonic is essential for the treatment of PPH due to atony, it considered that misoprostol may be used until oxytocin can be made available.
- The Consultation noted that the doses of misoprostol used in the trials on prevention of PPH ranged from 200 µg to 800 µg, administered orally, sublingually or rectally. In the PPH treatment trials, doses from 600 µg to 1000 µg were administered orally, sublingually or rectally. Side-effects, primarily high fever and shivering, were associated with higher doses; few life-threatening events have been reported. Hence, doses of 1000-1200 µg are not recommended. The Consultation noted that the largest trial of misoprostol for treatment of PPH (35) reported use of a dose of 800 µg, given sublingually. The majority of the participants felt that, in the treatment of PPH, where the first- and second-line uterotonics are not available or have failed, as a last resort 800 µg can be used. However, three members strongly disagreed with this conclusion because

<sup>1</sup> Final numbers were confirmed after the meeting by Gynuity.

of concerns about safety. Because of the disagreement the discussion of dose is included here, rather than as a recommendation.

- In view of the uncertainty and disagreement among the participants regarding the safe dose of misoprostol, WHO will commission a further review of misoprostol doses and routes of administration.

### ***(c) Should tranexamic acid be offered in the treatment of PPH due to uterine atony?***

Tranexamic acid is an antifibrinolytic agent that has been on the market for several decades. Antifibrinolytic agents are widely used in surgery to reduce blood loss. A systematic review of randomized controlled trials of antifibrinolytic agents in elective surgery showed that tranexamic acid reduced the risk of blood transfusion by 39% (36). Another Cochrane review showed that tranexamic acid reduced heavy menstrual bleeding without side-effects (37).

#### **Summary of evidence**

There have been no RCTs on the use of tranexamic acid for the treatment of PPH following vaginal delivery that address the priority outcomes. Tranexamic acid has been evaluated as prophylaxis following caesarean section in one RCT (38). The average blood loss in the two hours after the caesarean section was  $42.75 \pm 40.45$  ml in the study group and  $73.98 \pm 77.09$  ml in the control group.

One case report was found of a woman given tranexamic acid for treatment of massive postpartum haemorrhage after caesarean section (39).

#### **Recommendation**

Tranexamic acid may be offered as a treatment for PPH if: (i) administration of oxytocin, followed by second-line treatment options and prostaglandins, has failed to stop the bleeding; or (ii) it is thought that the bleeding may be partly due to trauma. (Quality of evidence: very low. Strength of recommendation: weak.)

#### **Remarks**

Evidence for this recommendation was extrapolated from the literature on surgery and trauma, which shows tranexamic acid to be a safe option in trauma-related bleeding.

The benefits of use of tranexamic acid in PPH treatment should be investigated in research studies.

### ***(d) Should recombinant factor VIIa be offered in the treatment of PPH due to uterine atony?***

Recently, recombinant factor VIIa (rFVIIa) has generated interest as an option for treatment of PPH, mainly in industrialized countries. The evidence regarding its use in the treatment of PPH is limited to reviews of case reports and case series (40, 41) and two observational studies (42,43) (page 30, [GRADE Table B3](#)).

Hossain (43) described a retrospective cohort study of 34 patients with more than 1500 ml blood loss in which 18 were treated with rFVIIa. Ahonen (42) compared the outcomes of 26 women who received rFVIIa to those of 22 women treated in the same time period for PPH without rFVIIa.

Both studies included women who had had caesarean section as well as women who had had a vaginal birth. The causes of PPH included uterine atony as well as abnormal placentation, retained placenta, and cervical or vaginal lacerations. The women had received conventional treatments, such as uterotonics, uterine massage, arterial ligation and, in some cases, hysterectomy prior to the administration of rFVIIa.

The risk of maternal death appeared to be lower in women treated with rFVIIa (OR 0.38, 95%CI 0.09-1.60), and remained lower following adjustment for baseline haemoglobin and activated partial thromboplastin time (aPTT) (OR 0.04, 95%CI 0.002-0.83) (43). The risk of subsequent need for hysterectomy is difficult to ascertain, as the drug was administered as a 'last resort' treatment. The authors note that as confidence in its use increased, rFVIIa began to be offered prior to hysterectomy. In Ahonen's report (42), 8 women received rFVIIa following hysterectomy, but none of the remaining 18 women treated with rFVIIa subsequently underwent hysterectomy.

A high rate of thrombotic events (185 events in 165 treated patients) has been reported in patients receiving rFVIIa for off-label use (44). Ahonen (42) described one report of a pulmonary embolus; the woman was subsequently diagnosed with antithrombin deficiency.

The Consultation discussed the evidence from observational studies and heard about ongoing research on rFVIIa.

### Recommendation

The Consultation agreed that there was not enough evidence to make any recommendation regarding the use of recombinant factor VIIa for the treatment of PPH. Recombinant factor VIIa for the treatment of PPH should be limited to women with specific haematological indications.

### Remark

Use of rFVIIa could be life-saving, but it is also associated with life-threatening side-effects. Moreover, recombinant factor VIIa is expensive to buy and may be difficult to administer.

## 2. Non-medical interventions for management of PPH

A range of mechanical interventions to compress or stretch the uterus have been proposed, either as temporizing measures or as definitive treatment. These interventions are summarized below.

### *(a) Should uterine massage be offered in the treatment of PPH?*

Uterine massage as a therapeutic measure is defined as rubbing of the uterus manually over the abdomen sustained until bleeding stops or the uterus contracts.

Initial rubbing of the uterus and expression of blood clots is not regarded as therapeutic uterine massage.

### Summary of evidence

There have been no RCTs on the use of uterine massage in the treatment of PPH. A case report series (45) and indirect evidence from one systematic review (46) on the use of uterine massage in PPH prevention were found.

In one RCT of the prophylactic use of uterine massage involving 200 women, massage was associated with a nonsignificant decrease in incidence of blood loss  $\geq 500$  ml (RR 0.52, 95%CI 0.16-1.67) and a significant reduction in the use of additional uterotonics (RR 0.20, 95%CI 0.08-0.50) (page 31, [GRADE Table B4](#)).

### Recommendation

Uterine massage should be started once PPH has been diagnosed. (Quality of evidence: very low. Strength of recommendation: strong.)

### Remarks

- Uterine massage to ensure the uterus is contracted and there is no bleeding is a component of active management of the third stage of labour for the prevention of PPH.
- The low cost and safety of uterine massage were taken into account in making this recommendation strong.

### *(b) Should bimanual uterine compression be offered in the treatment of PPH?*

#### Summary of evidence

No RCTs on the use of bimanual uterine compression in the treatment of PPH were identified. One case report (47) was found.

#### Recommendation

Bimanual uterine compression may be offered as a temporizing measure in the treatment of PPH due to uterine atony after vaginal delivery. (Quality of evidence: very low. Strength of recommendation: weak.)

#### Remark

The Consultation noted that health care workers would need to be appropriately trained in the application of bimanual uterine compression and that the procedure may be painful.

### *(c) Should uterine packing be offered in the treatment of PPH?*

#### Summary of evidence

No RCTs on the use of uterine packing in the treatment of PPH were found. Seven case series and one case report (48-55), with a total of 89 women (the largest involved 33 women), and four overviews were identified. Success rates (i.e. no need for hysterectomy or other invasive procedure) ranging from 75% to 100% are reported in these studies.

**Recommendation**

Uterine packing is not recommended for the treatment of PPH due to uterine atony after vaginal delivery. (Quality of evidence: very low. Strength of recommendation: weak.)

**Remark**

The Consultation noted that there was no evidence of benefit of uterine packing and placed a high value on concerns regarding its potential harm.

***(d) Should intrauterine balloon or condom tamponade be offered in the treatment of PPH?*****Summary of evidence**

There have been no RCTs on the use of uterine tamponade in the treatment of PPH. Nine case series and twelve case reports, evaluating 97 women (56-76), and two reviews were identified (77, 78). The instruments used included Sengstaken-Blakemore and Foley catheters, Bakri and Rusch balloons, and condoms.

Case series have reported success rates (i.e. no need for hysterectomy or other invasive procedure) ranging from 71% to 100%.

**Recommendation**

In women who have not responded to treatment with uterotonics, or if uterotonics are not available, intrauterine balloon or condom tamponade may be offered in the treatment of PPH due to uterine atony. (Quality of evidence: low. Strength of recommendation: weak.)

**Remark**

The Consultation noted that the application of this intervention requires training and that there are risks associated with the procedure, such as infection. The use of uterine balloon or condom tamponade in the treatment of PPH was considered a research priority.

***(e) Should external aortic compression be offered in the treatment of PPH?*****Summary of evidence**

No trials were found describing the use of external aortic compression in the treatment of PPH. A prospective study was performed in Australia to determine the haemodynamic effects of external aortic compression in nonbleeding postpartum women (79). Successful aortic compression, as documented by absent femoral pulse and unrecordable blood pressure in a lower limb, was achieved in 11 of 20 subjects. The authors concluded that the procedure is safe in healthy subjects and may be of benefit as a temporizing measure in treatment of PPH while resuscitation and management plans are made. Subsequently, one case report from Australia described the use of internal aortic compression as a temporizing measure to control severe PPH due to placenta percreta at the time of caesarean section (80).

**Recommendation**

External aortic compression for the treatment of PPH due to uterine atony after vaginal delivery may be offered as a temporizing measure until appropriate care is available. (Quality of evidence: very low. Strength of recommendation: weak.)

**Remarks**

- External aortic compression has long been recommended as a potential life-saving technique, and mechanical compression of the aorta, if successful, slows down blood loss.
- The Consultation placed a high value on the procedure as a temporizing measure in treatment of PPH.

**(f) Should nonpneumatic antishock garments be offered in the treatment of PPH?****Summary of evidence**

There have been no RCTs on the use of pneumatic or nonpneumatic antishock garments in the treatment of PPH. Case studies and case series have, however, been published and summarized (81-87). The use of nonpneumatic antishock garments (NASGs) has been reported in a before-and-after study of 634 women with obstetric haemorrhage (43% with uterine atony) in Egypt (88).

Women treated with an NASG had a median blood loss 200 ml lower (range 300-100 ml lower) than women who received standard treatment (hydration with intravenous fluids, transfusion, uterotonics, vaginal or abdominal surgery, as needed) in the “before” period (i.e. before the introduction of NASG). The risk of blood transfusion was higher in those treated with NASG (RR 1.23, 95%CI 1.06-1.43); the risk of surgical procedures was not statistically significantly different (RR 1.35, 95%CI 0.90-2.02) (page 31, **GRADE Table B5**).

A cluster RCT (Miller S, personal communication) is under way in Zambia and Zimbabwe to examine whether early application of an NASG by midwives prior to transfer to a referral hospital can decrease morbidity and mortality. No data were available for review.

**Recommendation**

The Consultation decided not to make a recommendation on this question.

**Remark**

The Consultation noted that research was ongoing to evaluate the potential benefits and harms of this intervention, and decided not to make a recommendation until these research results become available.

**(g) Should uterine artery embolization be offered in the treatment of PPH?**

Percutaneous transcatheter arterial embolization of the uterine artery has been reported from institutions that have adequate radiological facilities for this intervention.

### Summary of evidence

There have been no RCTs on the use of arterial embolization in the treatment of PPH. One retrospective cohort study (89) compared 15 women treated with embolization with 14 women receiving other treatments for PPH. The majority of these patients had been transferred from local hospitals. Ten of 13 women were successfully treated for PPH with arterial embolization. Of 11 women originally treated with conservative surgical methods, two subsequently underwent arterial embolization; one of these was successful while the second patient eventually required hysterectomy. Eighteen case series and 15 case reports (90-122) have been published, describing the intervention in 340 women. Studies report success rates (i.e. no need for hysterectomy or other invasive procedures) ranging from 82% to 100% (page 32, [GRADE Table B6](#)).

### Recommendation

If other measures have failed and resources are available, uterine artery embolization may be offered as a treatment for PPH due to uterine atony. (**Quality of evidence: very low. Strength of recommendation: weak.**)

### Remark

Uterine artery embolization requires significant resources, in terms of cost of treatment, facilities and training of health care workers.

## 3. Surgical interventions in the treatment of PPH

A wide range of surgical interventions have been reported to control postpartum haemorrhage that is unresponsive to medical or mechanical interventions. They include various forms of compression sutures, ligation of the uterine, ovarian or internal iliac artery, and subtotal or total hysterectomy.

### Summary of evidence

There have been no RCTs on the use of uterine compressive sutures in the treatment of PPH. Thirteen case series and twelve case reports describing a total of 113 women were identified (123-147). Eight overviews on compression sutures have also been published (77, 78, 148-153). The B-Lynch technique seems to be the most commonly reported procedure. Success rates (i.e. no need for hysterectomy or other invasive procedure) range from 89% to 100%.

Similarly, no RCTs on the use of selective artery ligation in treatment of PPH were identified. Twenty-one case series and 13 case reports have been published, describing the intervention in 532 women (123, 154-186). Studies report success rates (i.e. no need for hysterectomy or other invasive procedure) ranging from 62% to 100%.

### Recommendation

If bleeding does not stop in spite of treatment with uterotonics, other conservative interventions (e.g. uterine massage), and external or internal pressure on the uterus, surgical interventions should be initiated. Conservative approaches should be tried first, followed - if these do not work - by more invasive procedures. For example,

compression sutures may be attempted first and, if that intervention fails, uterine, utero-ovarian and hypogastric vessel ligation may be tried. If life-threatening bleeding continues even after ligation, subtotal (also called supracervical or total hysterectomy) should be performed. **(Quality of evidence: no formal scientific evidence of benefit or harm. Strength of recommendation: strong.)**

### Remark

The Consultation acknowledged that the level of skill of the health care providers will play a role in the selection and sequence of the surgical interventions.

## C. Management of retained placenta

### 1. Should uterotonics be offered as treatment for retained placenta?

#### Summary of evidence

One double-blind RCT was found that compared sulprostone with placebo in 50 women with retained placenta (187). Originally designed to recruit over 100 patients, the trial was stopped prematurely and sulprostone was given to all remaining cases.

The authors reported a lower risk of manual removal of the placenta (RR 0.51, 95%CI 0.34-0.86) and an increased risk of blood transfusion in the sulprostone group (RR 2.26, 95%CI 1.14-4.12) (page 33, **GRADE Table C1**). There is no empirical evidence for or against the use of other uterotonics for treatment of retained placenta.

#### Recommendations

- If the placenta is not expelled spontaneously, clinicians may offer 10 IU of oxytocin in combination with controlled cord traction. **(No formal scientific evidence of benefit or harm. Strength of recommendation: weak.)**
- Ergometrine is not recommended, as it may cause tetanic uterine contractions, which may delay expulsion of the placenta. **(Quality of evidence: very low. Strength of recommendation: weak.)**
- The use of prostaglandin E2 (dinoprostone or sulprostone) is not recommended. **(Quality of evidence: very low. Strength of recommendation: strong.)**

#### Remarks

- The Consultation found no empirical evidence to support recommendation of uterotonics for the management of retained placenta in the absence of haemorrhage. The above recommendation was reached by consensus.
- The WHO guide, *Managing complications in pregnancy and childbirth* (18), states that if the placenta is not expelled within 30 minutes after delivery of the baby, the woman should be diagnosed as having retained placenta. Since there is no evidence for or against this definition, the delay used to diagnose this condition is left to the judgement of the clinician.

- The same guide also recommends that, in the absence of haemorrhage, the woman should be observed for a further 30 minutes following the initial 30 minutes, before manual removal of the placenta is attempted. The Consultation noted that, in the absence of bleeding, spontaneous expulsion of the placenta can still occur; thus, a conservative approach is advised and the timing of manual removal as the definitive treatment is left to the judgement of the clinician.
- The recommendation about prostaglandin E2 is based on the lack of evidence, as well as concerns regarding adverse events, notably cardiac events.

## 2. Should intra-umbilical vein injection of oxytocin with or without saline be offered as treatment for retained placenta?

### Summary of evidence

One systematic review on umbilical vein injection for the management of retained placenta has been published (188). RCTs comparing the use of intraumbilical vein injection of saline with expectant management (four studies, 413 women), intraumbilical vein injection of saline+oxytocin with expectant management (five studies, 454 women), and intraumbilical vein injection of saline+oxytocin with saline (ten studies, 649 women) were identified.

The results of one unpublished study (189) were made available to the Consultation by the investigators. In this multicentre trial, 577 women in Pakistan, Uganda and the United Kingdom were randomized to receive either intraumbilical vein injection of 50 IU of oxytocin in 30 ml of saline ( $n=292$ ) or matching placebo ( $n=285$ ).

#### *Intraumbilical vein injection of saline versus expectant management*

There were no significant differences in rates of manual removal of the placenta (RR 0.97, 95%CI 0.83-1.19), blood loss  $\geq 500$  ml (RR 1.04, 95%CI 0.55-1.96), blood loss  $\geq 1000$  ml (RR 0.73, 95%CI 0.17-3.11), or blood transfusion (RR 0.76, 95%CI 0.41-1.39) (page 34, [GRADE Table C2](#)).

#### *Intraumbilical vein injection of saline+oxytocin versus expectant management*

There was a slightly lower rate of manual removal of the placenta in the group given saline+oxytocin, although the difference was not statistically significant (RR 0.86, 95%CI 0.72-1.01). Rates of blood loss  $\geq 500$  ml (RR 1.53, 95%CI 0.78-2.67), blood loss  $\geq 1000$  ml (RR 1.29, 95%CI 0.38-4.34), and blood transfusion (RR 0.89, 95%CI 0.5-1.58) were similar with wide confidence intervals (page 35, [GRADE Table C3](#)).

#### *Intraumbilical vein injection of saline+oxytocin versus saline*

There was a lower risk of manual removal of the placenta in the group given saline+oxytocin (RR 0.79, 95%CI 0.69-0.91). No differences were found in rates of blood loss  $\geq 500$  ml (RR 1.43, 95%CI 0.83-2.45), blood loss  $\geq 1000$  ml (RR 1.71, 95%CI 0.45-6.56) or blood transfusion (RR 1.17, 95%CI 0.63-2.19) and the confidence intervals were wide because there were few events (page 36, [GRADE Table C4](#)).

The unpublished RELEASE trial (189) data showed no benefit of intraumbilical vein injection of saline with oxytocin over placebo in terms of manual removal of the placenta (RR 0.98, 95%CI 0.87-1.12), blood loss  $\geq 500$  ml (RR 0.98, 95%CI 0.78-1.23), blood loss  $\geq 1000$  ml (RR 1.09, 95%CI 0.67-1.76) and blood transfusion (RR 0.77, 95%CI 0.46-1.26) (page 37, **GRADE Table C5**).

### Recommendations

- Intraumbilical vein injection of oxytocin with saline may be offered for the management of retained placenta. (**Quality of evidence: moderate. Strength of recommendation: weak.**)
- If, in spite of controlled cord traction, administration of uterotonics and intraumbilical vein injection of oxytocin+saline, the placenta is not delivered, manual extraction of the placenta should be offered as the definitive treatment. (**No formal assessment of quality of evidence. Strength of recommendation: strong.**)

### Remarks

- During the discussion on this topic, a new meta-analysis of the available data was performed, by including data from the recent large unpublished study with the existing published meta-analysis. Sensitivity analyses by quality of data and a fixed-versus-random-effects analysis were also conducted. In all these secondary analyses, the summary estimate reflected a modest effect, with the relative risk of manual removal being 0.89 (95%CI 0.81-0.98) with a fixed-effect model and 0.82 (95%CI 0.68-0.98) with a random-effect model. The Consultation was concerned about the possibility of publication bias in the meta-analysis, and was split between making a weak recommendation and not recommending intra-umbilical vein injection of oxytocin+saline.
- The Consultation recommended by a majority the use of umbilical vein injection of oxytocin+saline for retained placenta. In making the recommendation, the Consultation considered the advantages of avoiding an invasive intervention, such as manual removal of the placenta, and the low cost and absence of any side-effects with umbilical vein injection. It was noted that a potential disadvantage was that this intervention may delay the administration of other effective interventions. These considerations should be taken into account in the local adaptation of these guidelines.

## 3. Should antibiotics be offered after manual extraction of the placenta as part of the treatment of retained placenta?

### Summary of evidence

A systematic review of antibiotic prophylaxis after manual removal of the placenta, published in 2006, found no RCTs (190).

One retrospective study (191) of 550 patients evaluated prophylactic antibiotic therapy in intrauterine manipulations (such as forceps delivery, manual removal of the placenta and exploration of the cavity of the uterus) during vaginal delivery.

### Recommendation

A single dose of antibiotics (ampicillin or first-generation cephalosporin) should be offered after manual removal of the placenta. (Quality of evidence: very low. Strength of recommendation: strong.)

### Remarks

- Direct evidence of the value of antibiotic prophylaxis after manual removal of the placenta was not available. The Consultation considered indirect evidence of the benefit of prophylactic antibiotics from studies of caesarean section (192) and abortion, and observational studies of other intrauterine manipulations.
- Current practice suggests that ampicillin or first-generation cephalosporin may be administered when manual removal of the placenta is performed.
- This question was identified as a research priority for settings in which prophylactic antibiotics are not routinely administered and those with low infectious morbidity.

## D. Choice of fluid for replacement or resuscitation

### 1. Should crystalloids be offered for fluid replacement in women with PPH?

Fluid replacement is an important component of resuscitation for women with PPH, but the choice of fluid is controversial. Although outside the initial scope of these guidelines, this question was put to the Consultation in view of its importance.

#### Summary of evidence

There have been no RCTs comparing the use of colloids with other replacement fluids for resuscitation of women with PPH. There is indirect evidence from a Cochrane review that evaluated 63 trials on the use of colloids in the resuscitation of critically ill patients who required volume replacement secondary to trauma, burns, surgery, sepsis and other critical conditions (193). A total of 55 trials reported data on mortality for the following comparisons.

#### *Colloids versus crystalloids*

No statistical difference in the incidence of mortality was found when albumin or plasma protein fraction (23 trials, 7754 patients, RR 1.01, 95%CI 0.92-1.10), hydroxyethyl starch (16 trials, 637 patients, RR 1.05, 95%CI 0.63-1.75), modified gelatin (11 trials, 506 patients, RR 0.91, 95%CI 0.49-1.72), or dextran (nine trials, 834 patients, RR 1.24, 95%CI 0.94-1.65) were compared with crystalloids (page 38, **GRADE Table D1**).

#### *Colloid versus hypertonic crystalloid*

One trial, which compared albumin or plasma protein fraction with hypertonic crystalloid, reported one death in the colloid group (RR 7.00, 95%CI 0.39-126.92). Two trials that compared hydroxyethyl starch and modified gelatin with crystalloids

observed no deaths among the 16 and 20 participants, respectively (page 39, [GRADE Table D2](#)).

#### *Colloids in hypertonic crystalloid versus isotonic crystalloid*

The outcome of death was reported in eight trials, including 1283 patients, which compared dextran in hypertonic crystalloid with isotonic crystalloid (RR 0.88, 95%CI 0.74-1.05) and in one trial with 14 patients (page 39, [GRADE Table D3](#)).

#### **Recommendation**

Intravenous fluid replacement with isotonic crystalloids should be used in preference to colloids for resuscitation of women with PPH. (**Quality of evidence: low. Strength of recommendation: strong.**)

#### **Remark**

Available evidence suggests that high doses of colloids, which are more expensive than isotonic crystalloids, may cause adverse effects.

## **E. Health systems and organizational interventions**

### **1. Should health care facilities have a protocol for management of PPH?**

#### **Summary of evidence**

The literature search did not reveal any research evidence for or against the use of PPH management protocols. Although no systematic review was carried out, the Consultation considered that management protocols are generally useful and unlikely to be harmful.

#### **Recommendation**

Health care facilities should adopt a formal protocol for the management of PPH. (**Quality of evidence: no formal evidence reviewed; consensus. Strength: strong.**)

#### **Remark**

The Consultation acknowledged that the implementation of formal protocols is a complex process, which will require local adaptation of general guidelines.

### **2. Should health care facilities have a formal protocol for referral of women diagnosed as having PPH?**

#### **Summary of evidence**

The literature search did not reveal any research evidence for or against the use of PPH referral protocols. Although no systematic review was carried out, the Consultation considered that referral protocols are generally useful and unlikely to be harmful.

#### **Recommendation**

Health care facilities should adopt a formal protocol for patient referral to a higher level of care. (**Quality of evidence: no formal evidence reviewed; consensus. Strength of recommendation: strong.**)

### 3. Should simulation of PPH treatment be part of training programmes for health care providers?

#### Summary of evidence

The literature search did not reveal any research evidence for or against the use of PPH simulation programmes. Although no systematic review was carried out, the Consultation considered that PPH simulation programmes are generally useful and unlikely to be harmful.

#### Recommendation

Simulations of PPH treatment may be included in pre-service and in-service training programmes. (Quality of evidence: no formal evidence reviewed; consensus. Strength of recommendation: weak.)

#### Remarks

This recommendation is extrapolated from non-obstetric literature.

The Consultation placed a high value on the costs of simulation programmes acknowledging that there are different types of simulation programmes. Some of those programmes are hi-tech, computerized and costly while others are less expensive and more likely to be affordable in low and middle income countries.

The Consultation identified improvement in communication between health care providers and patients and their family members as an important priority in training of health care providers in PPH management.

The Consultation identified this area as a research priority.

## ► PPH care pathways

Postpartum haemorrhage can present in different clinical scenarios. Bleeding may be immediate and in large amounts, it may be slow and unresponsive to treatments, or it may be associated with systemic problems, such as clotting disorders. The recommendations related to PPH prevention, namely, active management of the third stage of labour, should be routinely applied (1).

It is critical that health workers remain vigilant during the minutes and hours following birth, in order to identify problems quickly. The care pathways presented (see insert) assume the presence of a skilled caregiver and a facility with basic surgical capacity. A stepwise approach is recommended. The initial step is to assess the woman and take immediate nonspecific life-saving measures, such as resuscitation, calling for help and monitoring vital signs. The second step is to give directive therapy following the diagnosis of PPH. In a given clinical situation, not all diagnostic assessments can be done simultaneously. The caregiver should assess the situation according to the circumstances surrounding the birth and immediate subsequent events.

The causes of PPH can be broadly classified into problems with uterine tone (atony), retained placenta, trauma (of the lower genital tract and uterus), and coagulation problems, which may be pre-existing or acquired as a result of other pathology (such as disseminated intravascular coagulation). If the birth was assisted with forceps or vacuum extraction, the likelihood of trauma will be higher. Alternatively, if labour was prolonged, uterine atony may be more likely. The care pathways suggest starting with the more effective, less invasive and less costly measures and, if those fail to stop the bleeding, moving towards invasive and more costly methods that require expertise and specific facilities.

It is acknowledged that some facilities will not have the expertise and equipment to undertake all the steps on the care pathways. The recommendations represent essential steps that should be undertaken at facility level. In facilities with more limited capacity, transfer of women with haemorrhage to a higher care facility should be organized without delay.

## Methodology

The following algorithms were reviewed:

- Managing complications in pregnancy and childbirth (18).
- Algorithm presented as an attachment to the *Textbook of postpartum hemorrhage* (194).
- Algorithm of the Society of Obstetricians and Gynaecologists, Canada (195).
- French PPH management guideline (196).
- Argentinian PPH management algorithm (197).
- Guideline for the management of post-partum haemorrhage in the community (version 2.1.1) of Good Hope Hospital (198).
- Essential O&G Guidelines for district hospitals, South Africa (199).
- Guidelines for obstetric care at Coronation, Johannesburg and Natalspruit Hospitals, South Africa (200).

Draft care pathways were produced by the Secretariat and adjusted according to the recommendations made by the Consultation on uterotonics, mechanical measures to compress or stretch the uterine musculature, other pharmaceutical approaches, such as tranexamic acid, and surgery.

The Consultation agreed to follow the stepwise approach adopted in the Canadian guidelines. This approach identifies the initial measures, and moves to more invasive, costly and risky interventions only if the directed therapy for the diagnosed pathology fails. The approach taken by the Consultation assumes that more than one pathology may exist in one patient, and that the care provider should be vigilant in looking for other pathologies. The potential existence of additional pathologies will be more relevant if the initial therapeutic approaches fail, as the possibility

of both an existing (undiagnosed) pathology and the development of a new one (e.g. coagulopathy) increase as time passes.

Therapeutic approaches related to partially retained placenta, traumatic haemorrhage and coagulopathies are included in the care pathways but not in the recommendations. For these, there was no formal search for evidence, appraisal and review, and the recommendations in the care pathways reflect the consensus of the Consultation.

The Consultation considered it important to highlight the emergency resuscitation measures in the care pathways. While not all PPH cases are associated with massive blood loss and shock, the health care worker should be aware that large blood losses can occur within a short period and that vigilance is needed at all times.

Some interventions are recommended as temporizing measures, especially during transfer of the patient to a higher level of care; occasionally, bleeding may stop with some of these measures.

It should be noted that for some categories, such as uterine atony, there is a hierarchy within the interventions listed in each group of directive therapy (uterotonics, mechanicals, surgery, etc.), starting with the more effective, less expensive methods with a larger safety margin.

## ► Research implications

The Consultation noted the questions for which the quality of evidence was low or very low. In general, the fact that recommended practices are based on evidence of low or very low quality would suggest that further research is needed. However, those areas may not be of high priority, for various reasons. The Consultation agreed that the following questions should be considered as high priority for research in the international community. (The list below is in order of discussion, not level of priority.)

### 1. Accuracy of blood loss assessment

The Consultation agreed that quantification of blood loss is important, and that it may be useful to study the level of blood loss that is considered as requiring active management of PPH (i.e. when should treatment be started?). The large data set compiled by Gynuity from their various studies could be scrutinized for this purpose before any primary research is undertaken.

### 2. Interventions

#### (a) Medications

The dosage of misoprostol generated a lot of discussion and disagreement, because of concerns over safety. Investigation of the effects of lower doses of misoprostol was suggested. However, given that oxytocin is clearly superior, such studies could only be conducted in places that have no access to oxytocin.

Clarification of the role of tranexamic acid in PPH and obstetric haemorrhage was identified as a priority. Some clinicians in the Consultation mentioned that they already use tranexamic acid, while others did not. There seems to be uncertainty among clinicians and an absence of evidence. The Consultation was informed that a large multicentre trial is planned.

### **(b) Procedures**

Uterine massage is recommended for routine care of women in the immediate postnatal period up to two hours. However, it has not been evaluated as a therapeutic option in a clearly defined way. Since this is a simple intervention that can even be self-administered, the Consultation considered that evaluating strategies to train health workers and mothers in the use of uterine massage would be worth while.

Balloon or condom tamponade for the treatment of PPH is highly valued by some practitioners, but not used at all by others. The Consultation considered that this intervention can be highly effective, but may also have potential complications; it should be rigorously evaluated as a priority.

The Consultation noted the lack of evidence regarding the role of antibiotics following manual extraction of a retained placenta. In settings where antibiotics are not currently routinely administered, it may be worth while to evaluate the benefits and harms.

### **(c) Training programmes**

The Consultation noted that there was no primary evidence on the effectiveness of training programmes in obstetric haemorrhage and agreed that evaluations of such programmes should be a priority, since they require financial and human resources.

### **(d) Implementation research**

The Consultation noted that some strategies for implementation of guidelines have been shown to be effective. However, there may be a need for new primary research projects in different contexts to study the implementation of these particular recommendations.

## **► Plans for local adaptation of the recommendations**

The WHO Department of Reproductive Health and Research works with international partners, including its collaborating centres and WHO country and regional offices, to promote the dissemination and adaptation of its recommendations. Specifically, the Department has been collaborating with the United Nations Population Fund (UNFPA) since 2004 in a Strategic Partnership Programme to support country-level adaptation and implementation of sexual and reproductive health guidelines. The Department

has also published a document, outlining the principles and processes of guideline adaptation and implementation (201).

The text of the recommendations and remarks points out where local adaptation might be considered.

## ► Plans for supporting implementation of these recommendations

These recommendations have been developed in collaboration with external partners and the International Federation of Obstetricians and Gynaecologists (FIGO). The current document will be distributed to all WHO regional and country offices. During 2009-2010, the recommendations will be presented in scientific meetings and a short summary will be published in a peer-reviewed journal. They will also be included on the Department's Website and in *The WHO Reproductive Health Library*, online and on CD-ROM, which reaches around 50 000 health workers. The care pathways for the management of PPH and retained placenta have been produced on a wallchart included in this publication and will be sent to all WHO country and regional offices and international partners.

The WHO Secretariat will collect comments on the quality, user-friendliness and implementation of these recommendations by seeking feedback from its collaborating institutions and WHO country and regional offices. An update of the recommendations is planned for 2010-2011.

## ► GRADE tables

- A. Diagnosis of PPH (Tables A1 and A2)
- B. Management of atonic PPH (Tables B1-B6)
- C. Management of retained placenta (Tables C1-C5)
- D. Choice of fluid for replacement or resuscitation (Tables D1-D3)

## A. Diagnosis of PPH

**Table A1.** Visual versus quantitative methods for estimating blood loss after vaginal delivery (3)

No. of studies	Quality assessment					Summary of findings				Importance		
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients				Quality	
							Visual estimation	Measured estimation	Relative (95% CI)			Effect
1	Randomized trial	Serious <sup>1</sup>	No serious inconsistency	Serious <sup>2</sup>	Serious <sup>3</sup>	Reporting bias <sup>4</sup>	61	62	-	Mean difference - 99.71 (-157.19 to -42.23)	⊕○○○ Very low	Important

<sup>1</sup> Method of allocation concealment not described.

<sup>2</sup> Related to settings where it is feasible to use the drape method.

<sup>3</sup> Wide range.

<sup>4</sup> Intervention not blinded.

**Table A2.** Training courses on estimating blood loss after vaginal delivery (13)

No. of studies	Quality assessment					Summary of findings				Importance		
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of subjects making accurate estimation				Quality	
							Attending training course on blood loss estimation	Controls	Relative (95% CI)			Effect
1	Randomized trial	Serious <sup>1</sup>	No serious inconsistency	Serious <sup>2</sup>	Serious <sup>3</sup>	None	34/45 (75.6%)	11/45 (24%)	RR 3.09 (1.80-5.30)	522 more per 1000 <sup>4</sup>	⊕○○○ Very low	Not important

<sup>1</sup> Methods of randomization and allocation concealment not described.

<sup>2</sup> Limited to setting; may be difficult to generalize.

<sup>3</sup> Wide confidence intervals.

<sup>4</sup> 522 more cases per 1000 accurately estimated.

## B. Management of atonic PPH

**Table B1.** Adjunct use of misoprostol in women who received prophylactic oxytocin in the third stage of labour (34)

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect		Quality	
							Primary outcomes	Controls	Relative (95% CI)	Absolute		
Additional blood loss $\geq 500$ ml												
4	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	170/929 (18.3%)	200/950 (21.1%)	RR 0.83 (0.64–1.07)	29 fewer per 1000	⊕⊕⊕⊕ High	Critical
Additional blood loss $\geq 1000$ ml												
3	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>1</sup>	None	20/899 (2.2%)	27/915 (3.1%)	RR 0.76 (0.43–1.34)	7 fewer per 1000	⊕⊕⊕○ Moderate	Critical
Blood transfusion												
4	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	138/927 (14.9%)	147/949 (14.5%)	RR 0.96 (0.77–1.19)	6 fewer per 1000	⊕⊕⊕⊕ High	Critical
Hysterectomy												
3	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Very serious <sup>1</sup>	None	5/900 (0.6%)	5/919 (0.4%)	RR 0.93 (0.16–5.41)	0 fewer per 1000	⊕⊕○○ Low	Critical
Additional uterotonics												
3	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	253/894 (28.3%)	271/910 (28.3%)	RR 0.96 (0.84–1.1)	11 fewer per 1000	⊕⊕⊕⊕ High	Critical
Shivering												
4	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>1</sup>	None	556/928 (59.9%)	270/948 (17.7%)	RR 2.24 (1.72–2.91)	219 more per 1000	⊕⊕⊕○ Moderate	Important

<sup>1</sup> Wide confidence interval.

**Table B2.** Misoprostol vs oxytocin for treatment of postpartum haemorrhage in women who did not receive prophylactic oxytocin in the third stage of labour (35)

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect		Quality	
							Misoprostol	Oxytocin	Relative (95% CI)	Absolute		
<b>Additional blood loss <math>\geq 500</math> ml</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	52/488 (10.7%)	19/489 (4%)	RR 2.74 (1.64-4.56)	69 more per 1000	⊕⊕⊕⊕ High	Critical
<b>Additional blood loss <math>\geq 1000</math> ml</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Very serious <sup>1</sup>	None	5/488 (1%)	3/489 (0.6%)	RR 1.67 (0.4-6.95)	4 more per 1000	⊕⊕○○ Low	Critical
<b>Blood transfusion</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>2</sup>	None	43/488 (8.8%)	28/489 (6%)	RR 1.54 (0.97-2.44)	32 more per 1000	⊕⊕⊕○ Moderate	Critical
<b>Additional uterotonics</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	59/489 (12.1%)	33/488 (7%)	RR 1.79 (1.19-2.69)	55 more per 1000	⊕⊕⊕⊕ High	Critical
<b>Temperature &gt; 40 °C</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	Serious <sup>3</sup>	Serious <sup>4</sup>	Strong association <sup>5</sup>	64/488 (13.1%)	0/489 (0%)	RR 129.27 (8.01-2883.1)	0 more per 1000	⊕⊕⊕○ Moderate	Critical

<sup>1</sup> From a 40% reduction to a sevenfold increase.

<sup>2</sup> From a 3% reduction to a 2.5-fold increase.

<sup>3</sup> Results concentrated in one setting.

<sup>4</sup> Although significant, confidence intervals are wide.

<sup>5</sup> Large effect in the intervention group.

**Table B3. Recombinant factor VIIa for treatment of postpartum haemorrhage (42, 43)**

No. of studies	Quality assessment						Summary of findings				Importance	
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No of patients			Quality		
							rFVIIa	Controls	Effect			
<b>Need for surgical treatment</b>												
2	Observational study	No serious limitations	No serious inconsistency	Serious <sup>1,2</sup>	Serious <sup>3</sup>	None	8/36 <sup>4</sup> (22.2%)	13/38 (34.2%)	OR 0.59 (0.19-1.77)	122 fewer per 1000 (from 264 fewer to 181 more)	⊕○○○ Very low	Critical
<b>Hysterectomy</b>												
2	Observational study	No serious limitations	No serious inconsistency	Serious <sup>1,2</sup>	Serious <sup>3</sup>	None	13/36 <sup>5</sup> (36.1%)	13/32 (40.6%)	OR 0.98 (0.34-2.57)	22 fewer per 1000 (from 244 fewer to 366 more)	⊕○○○ Very low	Critical
<b>Death</b>												
1	Observational study	No serious limitations	No serious inconsistency	Serious <sup>1,2</sup>	Serious <sup>3</sup>	None	5/50 (10%)	8/44 (18.2%)	OR 0.38 (0.09-1.6) <sup>6</sup>	107 fewer per 1000 (from 163 fewer to 88 more)	⊕○○○ Very low	Critical
<b>Procedure-related complications</b>												
1	Observational study	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>3</sup>	None	1/26 <sup>7</sup> (6.3%)	0/22 (0%)	OR 2.65 (0.10-68.30)	0 per 1000 (from 0 fewer to 0 more)	⊕⊕○○ Low	Critical

<sup>1</sup> Study included PPH following vaginal delivery and caesarean section.

<sup>2</sup> Study included PPH due to uterine atony, cervical tears, lacerations, abnormal placentation, and medical or pregnancy-related disorders.

<sup>3</sup> Wide confidence interval.

<sup>4</sup> Hossain study (43) did not indicate timing of rFVIIa administration in relation to need for procedure.

<sup>5</sup> Ahonen study (42) included 8 women who received rFVIIa after hysterectomy; they are not included here. No women required hysterectomy following rFVIIa administration.

<sup>6</sup> Authors also reported OR of maternal mortality adjusted for baseline haemoglobin and aPTT (OR=0.04, 95%CI: 0.002-0.83).

<sup>7</sup> One reported case of pulmonary embolism in patient subsequently diagnosed with antithrombin deficiency.

Table B4. Uterine massage for treatment of postpartum haemorrhage (46)

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect		Quality	
							Uterine massage	Controls	Relative (95% CI)	Absolute		
Blood loss $\geq 500$ ml (follow-up 1 hour; blood collected in plastic drapes)												
1	Randomized trial	Serious <sup>1</sup>	No serious inconsistency	Serious <sup>2</sup>	Serious <sup>3</sup>	None	4/98 (4.1%)	8/102 (8%)	RR 0.52 (0.16-1.67)	38 fewer per 1000	⊕○○○ Very low	critical
Additional uterotonics												
1	Randomized trial	Serious <sup>1</sup>	No serious inconsistency	Serious <sup>2</sup>	Serious <sup>3</sup>	None	5/98 (5.1%)	26/102 (25%)	RR 0.20 (0.08-0.50)	200 fewer per 1000	⊕○○○ Very low	

<sup>1</sup> Possibility of assessment bias. Small sample size.

<sup>2</sup> Intervention is for PPH prevention, not treatment.

<sup>3</sup> Wide confidence interval.

Table B5. Nonpneumatic antishock garment for treatment of postpartum haemorrhage (88)

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect		Quality	
							NASG	Controls (before)	Relative (95% CI)	Absolute		
Median blood loss (range of scores - better indicated by less)												
1	Before and after study	Serious <sup>1</sup>	No serious inconsistency	Serious	No serious imprecision	None	180	149	-	Median difference -200 ml (-300 to -100 ml)	⊕○○○ Very low	Important
Blood transfusion												
1	Before and after study	Serious <sup>1</sup>	No serious inconsistency	Serious	No serious imprecision	None	155/206 (75.2%)	96/158 (60.8%)	RR 1.23 (1.06-1.43)	140 more per 1000 (from 36 more to 261 more)	⊕○○○ Very low	Critical
Surgical procedures												
1	Before and after study	Serious <sup>1</sup>	No serious inconsistency	Serious	Serious <sup>2</sup>	None	51/206 (24.8%)	29/158 (18.4%)	RR 1.35 (0.90-2.02)	64 more per 1000 (from 18 fewer to 188 more)	⊕○○○ Very low	Critical

<sup>1</sup> "Before and after" design.

<sup>2</sup> From a 10% reduction to a twofold increase.

**Table B6. Uterine artery embolization for treatment of postpartum haemorrhage (89)**

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect		Quality	
							Uterine artery embolization	Control	Relative (95% CI)	Absolute		
<b>Hysterectomy</b>												
1	Observational study	No serious limitations	No serious inconsistency	Serious <sup>1</sup>	Serious <sup>2</sup>	None	4/15 <sup>3</sup> (26.7%)	2/9 (22.2%)	OR 1.27 (0.18-8.89)	48 more per 1000	⊕○○○ Very low	Critical
<b>Procedure-related complication</b>												
1	Observational study	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>2</sup>	None	1/15 <sup>4</sup> (6.7%)	0/14 (0%)	OR 1.97 (0.007-54.84)	0 per 1000	⊕○○○ Low	Critical

<sup>1</sup> Study included women who gave birth by caesarean section as well as women who had vaginal delivery.

<sup>2</sup> Wide confidence interval.

<sup>3</sup> Includes women treated with embolization after conservative surgical methods.

<sup>4</sup> Adverse event was rash caused by contrast material.

## C. Management of retained placenta

Table C1. Uterotonics for management of retained placenta (187)

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect		Quality	
							Uterotonics	Controls	Relative (95% CI)	Absolute		
<b>Manual removal of the placenta</b>												
1	Randomized trial	Very serious <sup>1</sup>	No serious inconsistency	No serious indirectness	No serious imprecision	None	11/24 (45.8%)	22/26 (84.6%)	RR 0.54 (0.34-0.86)	34 fewer per 1000 (from 195 fewer to 161 more)	⊕⊕○○ Low	Critical
<b>Blood transfusion</b>												
1	Randomized trial	Very serious <sup>1</sup>	No serious inconsistency	No serious indirectness	No serious imprecision	None	16/24 (66.7%)	8/26 (30%)	RR 2.26 (1.14-4.12)	378 more per 1000	⊕⊕○○ Low	Critical

<sup>1</sup> The study was stopped prematurely after “the null hypothesis of equal effectiveness of both treatments was rejected”. Interim analyses were made after each 5 consecutive patients. Small sample size. 15% of women excluded from analyses.

**Table C2. Intraumbilical vein injection of saline solution vs expectant management for retained placenta (188)**

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect		Quality	
							Intraumbilical vein injection of saline solution	Expectant management	Relative (95% CI)	Absolute		
<b>Manual removal of the placenta</b>												
4	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	114/206 (55.3%)	119/207 (58%)	RR 0.97 (0.83-1.19)	17 fewer per 1000	⊕⊕⊕⊕ High	Critical
<b>Blood loss ≥500 ml</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>1</sup>	None	15/62 (24.2%)	14/60 (23.3%)	RR 1.04 (0.55-1.96)	9 more per 1000	⊕⊕⊕○ Moderate	Critical
<b>Blood loss ≥ 1000 ml</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>2</sup>	None	3/62 (4.8%)	4/60 (7%)	RR 0.73 (0.17-3.11)	18 fewer per 1000	⊕⊕⊕○ Moderate	Critical
<b>Blood transfusion</b>												
2	Randomized trial	No serious limitations	Serious <sup>3</sup>	No serious indirectness	Serious <sup>4</sup>	None	15/118 (12.7%)	19/110 (17%)	RR 0.76 (0.41-1.39)	40 fewer per 1000	⊕⊕○○ Low	Critical

<sup>1</sup> Anything from a 45% reduction to a twofold increase.

<sup>2</sup> Anything from an 83% reduction to a threefold increase.

<sup>3</sup> No events in one trial.

<sup>4</sup> Anything from a 59% reduction to a 39% increase.

Table C3. Intraumbilical vein injection of saline + oxytocin vs expectant management for retained placenta (188)

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect		Quality	
							Intraumbilical vein injection with saline + oxytocin	Expectant management	Relative (95% CI)	Absolute		
<b>Manual removal of the placenta</b>												
5	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	117/234 (50%)	129/220 (59%)	RR 0.86 (0.72-1.01)	82 fewer per 1000	⊕⊕⊕⊕ High	Critical
<b>Blood loss ≥500 ml</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>1</sup>	None	25/70 (35.7%)	14/60 (23%)	RR 1.53 (0.78-2.67)	121 more per 1000	⊕⊕⊕○ Moderate	Critical
<b>Blood loss ≥1000 ml</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>2</sup>	None	6/70 (8.6%)	4/60 (6.7%)	RR 1.29 (0.38-4.34)	19 more per 1000	⊕⊕⊕○ Moderate	Critical
<b>Blood transfusion</b>												
2	Randomized trial	No serious limitations	Serious <sup>3</sup>	No serious indirectness	Serious <sup>4</sup>	None	18/120 (15%)	19/117 (16%)	RR 0.89 (0.5-1.58)	17 fewer per 1000	⊕⊕○○ Low	Critical

<sup>1</sup> Anything from a 22% reduction to a threefold increase.

<sup>2</sup> Anything from a 62% reduction to a more than fourfold increase.

<sup>3</sup> No events in one trial.

<sup>4</sup> Anything from a 50% reduction to a 58% increase.

**Table C4. Intraumbilical vein injection of saline + oxytocin vs saline for retained placenta (188)**

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect		Quality	
							Intraumbilical vein injection of saline + oxytocin	Intraumbilical vein injection of saline	Relative (95% CI)	Absolute		
<b>Manual removal of the placenta</b>												
10	Randomized trial	No serious limitations	Serious <sup>1</sup>	No serious indirectness	No serious imprecision	None	158/335 (47.2%)	184/314 (59%)	RR 0.79 (0.69-0.91)	123 fewer per 1000	⊕⊕⊕ Moderate	Critical
<b>Blood loss ≥ 500 ml</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>2</sup>	None	25/70 (35.7%)	15/60 (25%)	RR 1.43 (0.83-2.45)	107 more per 1000	⊕⊕⊕ Moderate	Critical
<b>Blood loss ≥ 1000 ml</b>												
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>3</sup>	None	6/70 (8.6%)	3/60 (5%)	RR 1.71 (0.45-6.56)	35 more per 1000	⊕⊕⊕ Moderate	Critical
<b>Blood transfusion</b>												
2	Randomized trial	No serious limitations	Serious <sup>4</sup>	No serious indirectness	Serious <sup>5</sup>	None	18/120 (15%)	15/118 (13%)	RR 1.17 (0.63-2.19)	22 more per 1000	⊕⊕⊕ Low	Critical

<sup>1</sup> Heterogeneity: I<sup>2</sup> = 45.5%.

<sup>2</sup> Anything from a 27% reduction to a 2.5-fold increase.

<sup>3</sup> Anything from a 55% reduction to a more than sixfold increase.

<sup>4</sup> No events in one trial.

<sup>5</sup> Anything from a 37% reduction to a twofold increase.

**Table C5. Intraumbilical vein injection of 50 IU oxytocin+30 ml saline vs placebo for retained placenta (189)**

No. of studies		Quality assessment							Summary of findings					Importance
		Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect		Quality		
								Intraumbilical vein injection of 50 IU oxytocin in saline	Placebo	Relative (95% CI)	Absolute			
<b>Manual removal of the placenta</b>														
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	179/292 (61.3%)	177/285 (62.1%)	RR 0.98 (0.87-1.12)	12 fewer per 1000 (from 81 fewer to 75 more)	⊕⊕⊕⊕ High	Critical		
<b>Blood loss ≥500 ml</b>														
1	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>1</sup>	None	99/292 (33.9%)	99/285 (34.7%)	RR 0.98 (0.78-1.23)	7 fewer per 1000 (from 76 fewer to 80 more)	⊕⊕⊕○ Moderate	Critical		
<b>Blood loss ≥1000 ml</b>														
1	randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>2</sup>	None	31/292 (10.6%)	28/285 (9.8%)	RR 1.09 (0.67-1.76)	9 more per 1000 (from 32 fewer to 74 more)	⊕⊕⊕○ Moderate	Critical		
<b>Blood transfusion</b>														
1	randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>3</sup>	None	43/292 (14.7%)	36/285 (12.6%)	RR 0.77 (0.46-1.26)	29 fewer per 1000 (from 68 fewer to 33 more)	⊕⊕⊕○ Moderate	Critical		

<sup>1</sup> Anything from a 22% reduction to a 23% increase.

<sup>2</sup> Anything from a 33% reduction to a 76% increase.

<sup>3</sup> Anything from a 54% reduction to a 26% increase.

## D. Choice of fluid for replacement or resuscitation

**Table D1.** Colloids vs crystalloids for fluid replacement in critically ill patients (193)

No. of studies	Quality assessment						Summary of findings				Importance	
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients		Effect			Quality
							Colloids	Crystalloids	Relative (95% CI)	Absolute		
<b>Death (albumin or plasma protein fraction vs crystalloids)</b>												
23	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	782/3870 (20.2%)	778/3884 (20%)	RR 1.01 (0.92-1.1)	2 more per 1000 (from 16 fewer to 20 more)	⊕⊕⊕⊕ High	Critical
<b>Death (hydroxyethyl starch vs crystalloids)</b>												
16	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	24/375 (6.4%)	18/262 (6.9%)	RR 1.05 (0.63-1.75)	3 more per 1000	⊕⊕⊕⊕ High	Critical
<b>Death (modified gelatin vs crystalloids)</b>												
11	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	13/224 (5.8%)	15/282 (5.3%)	RR 0.91 (0.49-1.72)	4 fewer per 1000	⊕⊕⊕⊕ High	Critical
<b>Death (dextran vs crystalloids)</b>												
9	Randomized trial	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	96/412 (23.3%)	57/422 (13.5%)	RR 1.24 (0.94-1.65)	32 more per 1000	⊕⊕⊕⊕ High	Critical

**Table D2. Colloids vs hypertonic crystalloids for fluid replacement in critically ill patients (193)**

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients			Quality		
							Colloid	Hypertonic crystalloid	Relative (95% CI)		Absolute	
<b>Deaths (albumin or plasma protein fraction vs hypertonic crystalloids)</b>												
1	Randomized trial	Very serious <sup>1</sup>	No serious inconsistency	No serious indirectness	Very serious	None	3/19 (15.8%)	0/19 (0%)	RR 7.00 (0.39-126.92)	0 per 1000	⊕○○○ Very low	Critical
<b>Deaths (hydroxyethyl starch vs crystalloids)</b>												
1	Randomized trial	Very serious <sup>1</sup>	No serious inconsistency	No serious indirectness	Very serious <sup>1</sup>	None	0/8 (0%)	0/8 (0%)	RR 0 (0-0)	0 per 1000	⊕○○○ Very low	Critical
<b>Deaths (modified gelatin vs hypertonic crystalloids)</b>												
1	Randomized trial	Very serious <sup>1</sup>	No serious inconsistency	No serious indirectness	Serious <sup>1</sup>	None	0/10 (0%)	0/10 (0%)	RR 0 (0-0)	0 per 1000	⊕○○○ Very low	Critical

<sup>1</sup> Underpowered study.

**Table D3. Colloid in hypertonic crystalloid vs isotonic crystalloid for fluid replacement in critically ill patients (193)**

No. of studies	Quality assessment							Summary of findings				Importance
	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No. of patients			Quality		
							Colloid in hypertonic crystalloid	Isotonic crystalloid	Relative (95% CI)		Absolute	
<b>Deaths (albumin or plasma protein fraction vs crystalloids)</b>												
1	randomized trial	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious	none	1/7 (14.3%)	2/7 (28.6%)	RR 0.50 (0.06-4.33)	143 fewer per 1000	⊕○○○ Very low	critical
<b>Deaths (dextran vs isotonic crystalloids)</b>												
8	randomized trial	no serious limitations <sup>2</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	182/667 (27.3%)	179/616 (29.1%)	RR 0.88 (0.74-1.05)	34 fewer per 1000	⊕⊕⊕⊕ High	critical

<sup>1</sup> Underpowered trial.

<sup>2</sup> As evaluated by the Cochrane reviewer.

## References

1. WHO recommendations for the prevention of postpartum haemorrhage. Geneva, World Health Organization, 2007 ([http://whqlibdoc.who.int/hq/2007/WHO\\_MPS\\_07.06\\_eng.pdf](http://whqlibdoc.who.int/hq/2007/WHO_MPS_07.06_eng.pdf), accessed 4 May 2009).
2. Atkins D et al. Grading quality of evidence and strength of recommendations. *British Medical Journal*, 2004, 328:1490-1494.

### Estimation of blood loss

3. Patel A et al. Drape estimation vs. visual assessment for estimating postpartum hemorrhage. *International Journal of Gynecology and Obstetrics*, 2006, 93:220-224.
4. Toledo P et al. The accuracy of blood loss estimation after simulated vaginal delivery. *Anesthesia and Analgesia*, 2007, 105:1736-1740.
5. Buckland SS, Homer CS. Estimating blood loss after birth: using simulated clinical examples. *Women Birth*, 2007, 20(2):85-88.
6. Larsson C et al. Estimation of blood loss after caesarean section and vaginal delivery has low validity with a tendency to exaggeration. *Acta Obstetrica et Gynecologica Scandinavica*, 2006, 85(12):1448-1452.
7. Bose P, Regan F, Paterson-Brown S. Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions. *BJOG: An International Journal of Obstetrics and Gynaecology*, 2006, 113(8):919-924.
8. Prasertcharoensuk W, Swadpanich U, Lumbiganon P. Accuracy of the blood loss estimation in the third stage of labour. *International Journal of Gynecology and Obstetrics*, 2000, 71(1):69-70.
9. Higgins PG. Measuring nurses' accuracy of estimating blood loss. *Journal of Advanced Nursing*, 1982, 7(2):157-162.
10. Tourné G et al. Intérêt de l'utilisation d'un sac de recueil dans le diagnostic des hémorragies de la délivrance. [Usefulness of a collecting bag for the diagnosis of post-partum hemorrhage.] *Journal de Gynécologie, Obstétrique et Biologie de la Reproduction*, 2004, 33:229-234.
11. Chua S et al. Validation of a laboratory method of measuring postpartum blood loss. *Gynecologic and Obstetric Investigation*, 1998, 46:31-33.
12. Duthie SJ et al. Discrepancy between laboratory determination and visual estimation of blood loss during normal delivery. *European Journal of Obstetrics and Gynecology and Reproductive Biology*, 38(2):119-124.
13. Sukprasert M et al. Increase accuracy of visual estimation of blood loss from education programme. *Journal of the Medical Association of Thailand*, 2006, 89(Suppl. 4): S54-S59.
14. Dildy GA 3rd et al. Estimating blood loss: can teaching significantly improve visual estimation? *Obstetrics and Gynecology*, 2004, 4(3):601-606.
15. Luegenbiehl DL. Improving visual estimation of blood volume on peripads. *MCN. The American Journal of Maternal Child Nursing*, 1997, 22(6):294-298.
16. Luegenbiehl DL et al. Standardized assessment of blood loss. *MCN. The American Journal of Maternal Child Nursing*, 1990, 15(4):241-244.

### Management of atonic PPH

17. Prendiville WJ, Elbourne D, McDonald S. Active versus expectant management in the third stage of labour. *Cochrane Database of Systematic Reviews*, 2000; Issue 2. Art. No.: CD000007.

### Medical interventions for PPH

18. *Managing complications in pregnancy and childbirth: a guide for midwives and doctors*. Geneva, World Health Organization, 2007.
19. Cotter A, Ness A, Tolosa J. Prophylactic oxytocin in the third stage of labour. *Cochrane Database of Systematic Reviews*, 2001; Issue 4. Art. No.: CD001808.
20. McDonald S, Abbott JM, Higgins SP. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. *Cochrane Database of Systematic Reviews*, 2004; Issue 1. Art. No.:CD000201.
21. Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. *Cochrane Database of Systematic Reviews*, 2007; Issue 3. Art. No.:CD005457.
22. Gülmezoglu AM et al. Prostaglandins for preventing postpartum haemorrhage. *Cochrane Database of Systematic Reviews*, 2007; Issue 3. Art. No.:CD000494.
23. Orji E et al. A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labour. *International Journal of Gynecology and Obstetrics*, 2008, 101(2):129-132.
24. de Groot AN et al. A placebo-controlled trial of oral ergometrine to reduce postpartum hemorrhage. *Acta Obstetrica et Gynecologica Scandinavica*, 1996, 75(5):464-468.
25. Howard WF, McFadden PR, Keettel WC. Oxytocic drugs in the fourth stage of labor. *JAMA: The Journal of the American Medical Association*, 1964, 189: 411-413.
26. Leung SW et al. A randomized trial of carbetocin versus syntometrine in the management of the third stage of labour. *British Journal of Obstetrics and Gynaecology*, 2006, 113(12):1459-1464.
27. Ngan L, Keong W, Martins R. Carbetocin versus a combination of oxytocin and ergometrine in control of postpartum blood loss. *International Journal of Gynaecology and Obstetrics*, 2007, 97(2): 152-153.
28. Poeschmann RP, Doesburg WH, Eskes TK. A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. *British Journal of Obstetrics and Gynaecology*, 1991, 98(6):528-530.
29. Van Selm M, Kanhai HH, Keirse MJ. Preventing the recurrence of atonic postpartum hemorrhage: a double-blind trial. *Acta Obstetrica et Gynecologica Scandinavica*, 1995, 74(4):270-274.
30. Nellore V, Mittal S, Dadhwal V. Rectal misoprostol vs. 15-methyl prostaglandin F2 alpha for the prevention of postpartum hemorrhage. *International Journal of Gynecology and Obstetrics*, 2006, 94(1):45-46.

31. Walraven G et al. Misoprostol in the treatment of postpartum haemorrhage in addition to routine management: a placebo randomized controlled trial. *British Journal of Obstetrics and Gynaecology*, 2004, 111(9):1014-1017.
32. Hofmeyr GJ et al. Misoprostol for treating postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357]. *BMC Pregnancy Childbirth*, 2004, 4(1):16.
33. Zuberi NF et al. Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital-based randomized-controlled trial in Karachi, Pakistan. *BMC Pregnancy Childbirth*, 2008 8:40.
34. Misoprostol to treat Postpartum Haemorrhage (PPH): a randomised controlled trial. ISRCTN34455240 (<http://apps.who.int/trialsearch/Trial.aspx?TrialID=ISRCTN34455240>).
35. Misoprostol for the Treatment of Primary Postpartum Hemorrhage Gynuity Health Projects. <http://clinicaltrials.gov/show/NCT00116350>.

#### Tranexamic acid

36. Henry DA et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. *Cochrane Database of Systematic Reviews*, 2007; Issue 4. Art. No.: CD001886.
37. Lethaby A, Farquhar C, Cookel. Antifibrinolytics for heavy menstrual bleeding. *Cochrane Database of Systematic Reviews*, 2000; Issue 4. Art. No.: CD000249.
38. Gai MY et al. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, 2004, 112(2):154-157.
39. As AK, Hagen P, Webb JB. Tranexamic acid in the management of postpartum haemorrhage. *British Journal of Obstetrics and Gynaecology*, 1996, 103(12):1250-1251.

#### Recombinant factor VIIa

40. Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. *British Journal of Obstetrics and Gynaecology*, 2007, 114(1): 8-15.
41. Franchini M et al. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. *Seminars in Thrombosis and Hemostasis*, 2008, 34(1):104-112.
42. Ahonen J, Jokela R, Kortila K. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage. *Acta Obstetrica et Gynecologica Scandinavica*, 2007, 51(7):929-936.
43. Hossain N et al. Use of recombinant activated factor VII for massive postpartum haemorrhage. *Acta Obstetrica et Gynecologica Scandinavica*, 2007, 86(10): 1200-1206.
44. O'Connell KA et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. *JAMA: The Journal of the American Medical Association*, 2006, 295(3):293-298.

#### Non-medical interventions for PPH

##### Uterine massage

45. Abdel-Aleem H et al. Uterine massage and postpartum blood loss. *International Journal of Gynecology and Obstetrics*, 2006, 93(3):238-239.
46. Hofmeyr GJ, Abdel-Aleem H, Abdel-Aleem MA. Uterine massage for preventing postpartum haemorrhage. *Cochrane Database of Systematic Reviews*, 2008; Issue 3. Art. No.: CD006431.

##### Bimanual uterine compression

47. Kovavisarch E, Kosolkittiwong S. Bimanual uterine compression as a major technique in controlling severe postpartum hemorrhage from uterine atony. *Journal of the Medical Association of Thailand*, 1997, 80(4):266-269.

##### Uterine packing

48. Bagga RJ et al. Uterovaginal packing with rolled gauze in postpartum hemorrhage. *Medscape General Medicine*, 2004, 6(1):50.
49. Haq G, Tayyab S. Control of postpartum and post abortal haemorrhage with uterine packing. *The Journal of the Pakistan Medical Association*, 2005, 55(9):369-371.
50. Hester JD. Postpartum hemorrhage and reevaluation of uterine packing. *Obstetrics and Gynecology*, 1975, 45(5):501-504.
51. Hsu SR et al. Use of packing in obstetric hemorrhage of uterine origin. *The Journal of Reproductive Medicine*, 2003, 48(2):69-71.
52. Naqvi S, Makhdoom T. Conservative management of primary postpartum haemorrhage. *Journal of the College of Physicians and Surgeons--Pakistan*, 2004, 14(5):296-297.
53. Nwagha UI, Okaro JM, Nwagha TU. Intraoperative uterine packing with mops: an effective, but under utilized method of controlling post partum haemorrhage - experience from South Eastern Nigeria. *Nigerian Journal of Medicine*, 2005, 14(3):279-282.
54. Wax JR, Channell JC, Vandersloot JA. Packing of the lower uterine segment - new approach to an old technique. *International Journal of Gynaecology and Obstetrics*, 1993, 43(2):197-198.
55. Wittich AC et al. Uterine packing in the combined management of obstetrical hemorrhage. *Military Medicine*, 1996, 161(3):180-182.

##### Balloon tamponade

56. Akhter S, Begum MR, Kabir J. Condom hydrostatic tamponade for massive postpartum hemorrhage. *International Journal of Gynaecology and Obstetrics*, 2005, 90(2):134-135.
57. Akhter S et al. Use of a condom to control massive postpartum hemorrhage. *Medscape General Medicine*, 2003, 5(3):38.

58. Bagga R et al. Postpartum hemorrhage in two women with impaired coagulation successfully managed with condom catheter tamponade. *Indian Journal of Medical Sciences*, 2007, 61(3):157-160.
59. Chan C et al. The use of a Sengstaken-Blakemore tube to control post-partum hemorrhage. *International Journal of Gynecology and Obstetrics*, 1997, 58(2):251-252.
60. Condie RG, Buxton EJ, Payne ES. Successful use of Sengstaken-Blakemore tube to control massive postpartum haemorrhage. *British Journal of Obstetrics and Gynaecology*, 1994, 101(11):1023-1024.
61. Condous GS et al. The "tamponade test" in the management of massive postpartum hemorrhage. *Obstetrics and Gynecology*, 2003, 101(4):767-772.
62. Dabelea V, Schultze PM, McDuffie RS Jr. Intrauterine balloon tamponade in the management of postpartum hemorrhage. *American Journal of Perinatology*, 2007, 24(6):359-364.
63. Danso D, Reginald P. Combined B-lynch suture with intrauterine balloon catheter triumphs over massive postpartum haemorrhage. *British Journal of Obstetrics and Gynaecology*, 2002, 109(8):963.
64. De Loor JA, van Dam PA. Foley catheters for uncontrollable obstetric or gynecologic hemorrhage. *Obstetrics and Gynecology*, 1996, 88(4 Pt 2):737.
65. Goldrath MH. Uterine tamponade for the control of acute uterine bleeding. *American Journal of Obstetrics and Gynecology*, 1983, 147(8):869-872.
66. Ikechebelu JI, Obi RA, Joe-Ikechebelu NN. The control of postpartum haemorrhage with intrauterine Foley catheter. *Journal of Obstetrics and Gynaecology*, 2005, 25(1):70-72.
67. Japaraj RP, Raman S. Sengstaken-Blakemore tube to control massive postpartum haemorrhage. *The Medical Journal of Malaysia*, 2003, 58(4):604-607.
68. Johanson R et al. Management of massive postpartum haemorrhage: use of a hydrostatic balloon catheter to avoid laparotomy. *British Journal of Obstetrics and Gynaecology*, 2001, 108(4):420-422.
69. Katesmark M, Brown R, Raju KS. Successful use of a Sengstaken-Blakemore tube to control massive postpartum haemorrhage. *British Journal of Obstetrics and Gynaecology*, 1994, 101(3):259-260.
70. Keriakos R, Mukhopadhyay A. The use of the Rusch balloon for management of severe postpartum haemorrhage. *Journal of Obstetrics and Gynaecology*, 2006, 26(4):335-338.
71. Marcovici I, Scoccia B. Postpartum hemorrhage and intrauterine balloon tamponade. A report of three cases. *Journal of Reproductive Medicine*, 1999, 44(2):122-126.
72. Nelson WL, O'Brien JM. The uterine sandwich for persistent uterine atony: combining the B-Lynch compression suture and an intrauterine Bakri balloon. *American Journal of Obstetrics and Gynecology*, 2007, 196(5):e9-10.
73. Seror J, Allouche C, Elhaik S. Use of Sengstaken-Blakemore tube in massive postpartum hemorrhage: a series of 17 cases. *Acta Obstetrica et Gynecologica Scandinavica*, 2005, 84(7):660-664.
74. Svigos J. A simple alternative measure to control severe post partum haemorrhage. *The Australian and New Zealand Journal of Obstetrics and Gynaecology*, 2004, 44(6):588
75. Turner GD. Uterine haemorrhage controlled by an intrauterine balloon insufflated with hot water. *Hospital Medicine*, 2002, 63(7):438.
76. Verkuyl DA. Fast and easy provisional treatment of severe postpartum haemorrhage. *British Journal of Obstetrics and Gynaecology*, 2007, 114(7):908-909.
77. Condous GS, Arulkumaran S. Medical and conservative surgical management of postpartum hemorrhage. *Journal of Obstetrics and Gynaecology Canada*, 2003, 25(11): 931-936.
78. Doumouchtsis SK et al. Systematic review of conservative management of postpartum hemorrhage: what to do when medical treatment fails. *Obstetrical and Gynecological Survey*, 2007, 62(8): 540-547.

#### External aortic compression

79. Riley DP, Burgess RW. External abdominal aortic compression: a study of a resuscitation manoeuvre for postpartum haemorrhage. *Anaesthesia and Intensive Care*, 1994, 22(5): 571-575.
80. Keogh J, Tsokos N. Aortic compression in massive postpartum haemorrhage - an old but lifesaving technique. *The Australian and New Zealand Journal of Obstetrics and Gynaecology*, 1997, 37(2): 237-238.

#### Nonpneumatic anti-shock garments

81. Brees C et al. Non-inflatable anti-shock garment for obstetric hemorrhage. *International Journal of Gynecology and Obstetrics*, 2004, 87(2):119-124.
82. Geller SE, Adams MG, Miller S. A Continuum of care model for postpartum hemorrhage. *International Journal of Fertility and Women's Medicine*, 2007, 52(2-3):97-105.
83. Hensleigh PA. Anti-shock garment provides resuscitation and haemostasis for obstetric haemorrhage. *British Journal of Obstetrics and Gynaecology*, 2002, 109(12):1377-1384.
84. Miller S, Lester F, Hensleigh P. Prevention and treatment of postpartum hemorrhage: new advances for low-resource settings. *Journal of Midwifery and Women's Health*, 2004, 49(4):283-92.
85. Miller S, Martin HB, Morris JL. Anti-shock garment in postpartum haemorrhage. *Best Practice and Research. Clinical Obstetrics and Gynaecology*, 2008, 22(6):1057-1074.
86. Tsu VD, Langer A, Aldrich T. Postpartum hemorrhage in developing countries: is the public health community using the right tools? *International Journal of Gynaecology and Obstetrics*, 2004, 85 (Suppl 1):S42-51.
87. Zhang BZ. [Anti-shock trousers in the management of gynecologic and obstetric hemorrhagic shock.] *Zhonghua Fu Chan Ke Za Zhi*, 1983, 18(4):229-231.
88. Miller S et al. First aid for obstetric haemorrhage: the pilot study of the non-pneumatic anti-shock garment in Egypt. *British Journal of Obstetrics and Gynaecology*, 2006, 113(4): 424-429.

### Uterine artery embolization

89. Vandelet P et al. [Limits to arterial embolization treatment of severe postpartum hemorrhage.] *Annales françaises d'anesthésie et de Réanimation*, 2001, 20(4):317-324.
90. Eriksson LG et al. Massive postpartum hemorrhage treated with transcatheter arterial embolization: technical aspects and long-term effects on fertility and menstrual cycle. *Acta Radiologica*, 2007, 48(6):635-642.
91. Soncini E et al. Uterine artery embolization in the treatment and prevention of postpartum hemorrhage. *International Journal of Gynaecology and Obstetrics*, 2007, 96(3):181-185.
92. Yong SP, Cheung KB. Management of primary postpartum haemorrhage with arterial embolisation in Hong Kong public hospitals. *Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi / Hong Kong Academy of Medicine*, 2006, 12(6):437-441.
93. Vegas G et al. Selective pelvic arterial embolization in the management of obstetric hemorrhage. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, 2006, 127(1):68-72.
94. Ojala K et al. Arterial embolization and prophylactic catheterization for the treatment for severe obstetric hemorrhage. *Acta Obstetrica et Gynecologica Scandinavica*, 2005, 84(11):1075-1080.
95. Tsang MLet al. Arterial embolisation in intractable primary post-partum haemorrhage: case series. *Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi / Hong Kong Academy of Medicine*. 2004, 10(5):301-306.
96. Bloom AI et al. Arterial embolisation for persistent primary postpartum haemorrhage: before or after hysterectomy? *British Journal of Obstetrics and Gynaecology* 2004, 111(8):880-884.
97. Boulleret C et al. Hypogastric arterial selective and superselective embolization for severe postpartum hemorrhage: a retrospective review of 36 cases. *Cardiovascular and Interventional Radiology*, 2004, 27(4):344-348.
98. Descargues G et al. Menses, fertility and pregnancy after arterial embolization for the control of postpartum haemorrhage. *Human Reproduction*, 2004, 19(2):339-343.
99. Hong TM et al. Uterine artery embolization: an effective treatment for intractable obstetric haemorrhage. *Clinical Radiology*, 2004, 59(1):96-101.
100. Cheng YY et al. Angiographic embolization for emergent and prophylactic management of obstetric hemorrhage: a four-year experience. *Journal of the Chinese Medical Association: JCMA*, 2003, 66(12):727-734.
101. Chung JW et al. Percutaneous transcatheter angiographic embolization in the management of obstetric hemorrhage. *The Journal of Reproductive Medicine*, 2003, 48(4):268-276.
102. Deux JF et al. Is selective embolization of uterine arteries a safe alternative to hysterectomy in patients with postpartum hemorrhage? *AJR. American Journal of Roentgenology*, 2001, 177(1):145-149.
103. Chen C, Ma B, Fang Y. Transcatheter arterial embolization in intractable postpartum hemorrhage. *Zhonghua Fu Chan Ke Za Zhi*, 2001, 36(3):133-136.
104. Pelage JP et al. Selective arterial embolization of the uterine arteries in the management of intractable post-partum hemorrhage. *Acta Obstetrica et Gynecologica Scandinavica*, 1999, 78(8):698-703.
105. Hansch E et al. Pelvic arterial embolization for control of obstetric hemorrhage: a five-year experience. *American Journal of Obstetrics and Gynecology*, 1999, 180(6 Pt 1):1454-1460.
106. Pelage JP et al. [Management of severe post-partum hemorrhage using selective arterial embolization.] *Journal de Gynécologie, Obstétrique et Biologie de la Reproduction*, 1999, 28(1):55-61.
107. Yamashita Y et al. Transcatheter arterial embolization of obstetric and gynaecological bleeding: efficacy and clinical outcome. *British Journal of Radiology*, 1994, 67(798):530-534.
108. Soyer P et al. Bilateral persistent sciatic artery: a potential risk in pelvic arterial embolization for primary postpartum hemorrhage. *Acta Obstetrica et Gynecologica Scandinavica*, 2005, 84(6):604-605.
109. Ødegaard E, Qvigstad E, Kløw NE [Intractable postpartum haemorrhage treated with selective arterial embolization.] *Tidsskrift for den Norske Laegeforening*, 2003, 123(19):2715-2716.
110. Cottier JP et al. Uterine necrosis after arterial embolization for postpartum hemorrhage. *Obstetrics and Gynecology*, 2002, 100(5 Pt 2):1074-1077.
111. Pirard C et al. Uterine necrosis and sepsis after vascular embolization and surgical ligation in a patient with postpartum hemorrhage. *Fertility and Sterility*, 2002, 78(2):412-413.
112. Murakami R et al. Transcatheter arterial embolization for postpartum massive hemorrhage: a case report. *Clinical Imaging*, 2000, 24(6):368-370.
113. Oei PL et al. Arterial embolization for bleeding following hysterectomy for intractable postpartum hemorrhage. *International Journal of Gynaecology and Obstetrics*, 1998, 62(1):83-86.
114. Hsu YR, Wan YL. Successful management of intractable puerperal hematoma and severe postpartum hemorrhage with DIC through transcatheter arterial embolization - two cases. *Acta Obstetrica et Gynecologica Scandinavica*, 1998, 77(1):129-131.
115. Glanz H. [Percutaneous catheter embolization in life threatening obstetrical hemorrhage - a case report.] *Geburtshilfe und Frauenheilkunde*, 1996, 56(9):504-507.
116. Devroede F et al. Arterial embolization of post-partum hemorrhage. *Journal Belge De Radiologie*, 1995, 78(6):337-338.
117. Marpeau L et al. [The role of pelvic arterial embolization in the treatment of severe postpartum hemorrhages.] *Journal de Gynécologie, Obstétrique et Biologie de la Reproduction*, 1992, 21(2):233-235.
118. Hori A et al. [Transcatheter arterial embolization for postpartum hemorrhage.] *Rinsho Hoshasen [Clinical Radiography]*, 1990, 35(5):645-647.
119. Ito M et al. [Angiographic arterial embolization for control of intractable postpartum hemorrhage.] *Nippon Sanka Fujinka Gakkai Zasshi*, 1989, 41(11):1859-1862.
120. Yamashita Y et al. [Transcatheter arterial embolization in postpartum hemorrhage.] *Nihon Igaku Hōshasen Gakkai Zasshi [Nippon Acta Radiologica]*, 1986, 46(8):1007-1011.

121. Brown BJ et al. Uncontrollable postpartum bleeding: a new approach to hemostasis through angiographic arterial embolization. *Obstetrics and Gynecology*, 1979, 54(3):361-365.
122. Heaston DK et al. Transcatheter arterial embolization for control of persistent massive puerperal hemorrhage after bilateral surgical hypogastric artery ligation. *AJR. American Journal of Roentgenology*, 1979, 133(1):152-154.

#### Compressive sutures

123. Api M, Api O, Yayla M. Fertility after B-Lynch suture and hypogastric artery ligation. *Fertility and Sterility*, 2005, 84(2):509.
124. B-Lynch C et al. The B-Lynch surgical technique for the control of massive postpartum haemorrhage: an alternative to hysterectomy? Five cases reported. *British Journal of Obstetrics and Gynaecology*, 1997, 104(3):372-375.
125. Cardone A et al. A new uterine suture technique for postpartum hemorrhage. *Minerva Ginecologica*, 2007, 59(3):343-346.
126. Cotzias C, Girling J. Uterine compression suture without hysterotomy - why a non-absorbable suture should be avoided. *Journal of Obstetrics and Gynaecology*, 2005, 25(2):150-152.
127. Dacus JV et al. Surgical treatment of uterine atony employing the B-Lynch technique. *The Journal of Maternal-Fetal Medicine*, 2000, 9(3):194-196.
128. Danso D, Reginald P. Combined B-lynch suture with intrauterine balloon catheter triumphs over massive postpartum haemorrhage. *British Journal of Obstetrics and Gynaecology*, 2002, 109(8):963.
129. Flam F, Sennström M. [Postpartum atony. A simple method prevents life-threatening hemorrhages.] *Lakartidningen*, 1998, 95(49):5650-5651.
130. Ghezzi F et al. The Hayman technique: a simple method to treat postpartum haemorrhage. *British Journal of Obstetrics and Gynaecology*, 2007, 114(3):362-365.
131. Goddard R, Stafford M, Smith JR. The B-Lynch surgical technique for the control of massive postpartum haemorrhage: an alternative to hysterectomy? Five cases reported. *British Journal of Obstetrics and Gynaecology*, 1998, 105(1):126.
132. Habek D et al. Successful of the B-Lynch compression suture in the management of massive postpartum hemorrhage: case reports and review. *Archives of Gynecology and Obstetrics*, 2006, 273(5):307-309.
133. Holtsema H et al. The B-Lynch technique for postpartum haemorrhage: an option for every gynaecologist. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, 2004, 115(1):39-42.
134. Malibary AM. Modified B-Lynch technique for the control of massive postpartum hemorrhage. An alternative to hysterectomy. *Saudi Medical Journal*, 2004, 25(12):1999-2000.
135. Mazhar SB, Yasmin S, Gulzar S. Management of massive postpartum hemorrhage by "B-Lynch" brace suture. *Journal of the College of Physicians and Surgeons Pakistan*, 2003, 13(1):51-52.
136. Nelson WL, O'Brien JM. The uterine sandwich for persistent uterine atony: combining the B-Lynch compression suture and an intrauterine Bakri balloon. *American Journal of Obstetrics and Gynecology*, 2007, 196(5):e9-10.
137. Ouahba J et al. Uterine compression sutures for postpartum bleeding with uterine atony. *British Journal of Obstetrics and Gynaecology*, 2007, 114(5):619-622.
138. Pereira A, et al. Compressive uterine sutures to treat postpartum bleeding secondary to uterine atony. *Obstetrics and Gynecology*, 2005, 106(3):569-572.
139. Pierzyński P et al. [B lynch suture for post partum haemorrhage due to uterine atony.] *Ginekologia Polska*, 2006, 77(2):146-150.
140. Saha R et al. B-Lynch brace suture simple surgical technique for managing post-partum haemorrhage - report of three cases. *Kathmandu University Medical Journal (KUMJ)*, 2005, 3(4):418-420.
141. Tjalma WA, Jacquemyn Y. Compression sutures instead of emergency peripartum hysterectomy. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, 2005, 118(2):258.
142. Treloar EJ et al. Uterine necrosis following B-Lynch suture for primary postpartum haemorrhage. *British Journal of Obstetrics and Gynaecology*, 2006, 113(4):486-488.
143. Tsitlakidis C et al. Ten year follow-up of the effect of the B-Lynch uterine compression suture for massive postpartum hemorrhage. *International Journal of Fertility and Women's Medicine*, 2006, 51(6):262-265.
144. Vangsgaard K. ["B-Lynch suture" in uterine atony.] *Ugeskrift for Laeger*, 2000, 162(24):3468.
145. Wergeland H, Alagic E, Løkvik B. [Use of the B-Lynch suture technique in postpartum hemorrhage.] *Tidsskrift for Den Norske Lægeforening: Tidsskrift for Praktisk Medicin, Ny Række*, 2002, 122(4):370-372.
146. Wohlmuth CT, Gumbs J, Quebral-Iviej J. B-Lynch suture: a case series. *International Journal of Fertility and Women's Medicine*, 2005, 50(4):164-173.
147. Wu HH, Yeh GP. Uterine cavity synechiae after hemostatic square suturing technique. *Obstetrics and Gynecology*, 2005, 105(5 Pt 2):1176-1178.
148. Price N, B-Lynch C. Technical description of the B-Lynch brace suture for treatment of massive postpartum hemorrhage and review of published cases. *International Journal of Fertility and Women's Medicine*, 2005, 50(4), 148-163.
149. Allam MS, B-Lynch C. The B-Lynch and other uterine compression suture techniques. *International Journal of Gynecology and Obstetrics*, 2005, 89(3): 236-241.
150. El-Hamamy E, B-Lynch C. A worldwide review of the uses of the uterine compression suture techniques as alternative to hysterectomy in the management of severe post-partum haemorrhage. *Journal of Obstetrics and Gynaecology*, 2005, 25(2): 143-149.
151. Sergent F et al. [Intractable postpartum haemorrhages: where is the place of vascular ligations, emergency peripartum hysterectomy or arterial embolization?]. *Gynécologie, Obstétrique et Fertilité*, 2004, 32(4): 320-329.
152. Tamizian O, Arulkumaran S. The surgical management of post-partum haemorrhage. *Best Practice and Research. Clinical Obstetrics and Gynaecology*, 2002, 16(1): 81-98.

153. Hayman RG, Arulkumaran S, Steer PJ. Uterine compression sutures: surgical management of postpartum hemorrhage. *Obstetrics and Gynecology*, 2002, 99(3): 502-506.

#### Selective artery ligation

154. Abd Rabbo SA. Stepwise uterine devascularization: a novel technique for management of uncontrolled postpartum hemorrhage with preservation of the uterus. *American Journal of Obstetrics and Gynecology*, 1994, 171(3):694-700.
155. Bolbos G, Sindos M. The Bolbos technique for the management of uncontrollable intra-caesarean uterine bleeding. *Archives of gynecology and obstetrics*, 2005, 272(2):142-144.
156. Casele HL, Laifer SA. Successful pregnancy after bilateral hypogastric artery ligation. A case report. *The Journal of Reproductive Medicine*, 1997, 42(5):306-308.
157. Chattopadhyay SK, Deb Roy B, Edrees YB. Surgical control of obstetric hemorrhage: hypogastric artery ligation or hysterectomy? *International Journal of Gynecology and Obstetrics*, 1990, 32(4):345-351.
158. Cinco Arenas JE et al. [Ligation of hypogastric arteries in obstetrics and gynecology. Report of 6 cases.] *Ginecología y Obstetricia de Mexico*, 1967, 22(133):1407-1417.
159. Clark SL et al. Hypogastric artery ligation for obstetric hemorrhage. *Obstetrics and Gynecology*, 1985, 66(3):353-356.
160. Das BN, Biswas AK. Ligation of internal iliac arteries in pelvic haemorrhage. *Journal of Obstetrics and Gynaecology Research*, 1998, 24(4):251-254.
161. Dubay ML, Holshouser CA, Burchell RC. Internal iliac artery ligation for postpartum hemorrhage: recanalization of vessels. *American Journal of Obstetrics and Gynecology*, 1980, 136(5):689-691.
162. Evans S, McShane P. The efficacy of internal iliac artery ligation in obstetric hemorrhage. *Surgery Gynecology and Obstetrics*, 1985, 160(3):250-253.
163. Fahmy K. Uterine artery ligation to control postpartum hemorrhage. *International Journal of Gynaecology and Obstetrics*, 1987, 25(5):363-367.
164. Fernandez H et al. Internal iliac artery ligation in post-partum hemorrhage. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, 1988, 28(3):213-220.
165. Hebisch G, Huch A. Vaginal uterine artery ligation avoids high blood loss and puerperal hysterectomy in postpartum hemorrhage. *Obstetrics and Gynecology*, 2002, 100(3):574-578.
166. Joshi VM et al. Internal iliac artery ligation for arresting postpartum haemorrhage. *British Journal of Obstetrics and Gynaecology*, 2007, 114(3):356-361.
167. Khelifi A et al. [Therapeutic ligation of hypogastric arteries: color Doppler follow-up] *Journal of Radiology*, 2000, 81(6):607-610.
168. Lédée N et al. Management in intractable obstetric haemorrhage: an audit study on 61 cases. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, 2001, 94(2):189-196.
169. Li YT et al. A useful technique for the control of severe caesarean hemorrhage: report of three cases. *Chang Gung Medical Journal*, 2002, 25(8):548-552.
170. Liberman Gia, Serova Ta. [Arrest of atonic hemorrhage in 3 parturients by bilateral ligation of the uterine arteries.] *Akusherstvo i ginekologiya*, 1963, 39:129-130.
171. Likeman RK. The boldest procedure possible for checking the bleeding - a new look at an old operation, and a series of 13 cases from an Australian hospital. *The Australian and New Zealand Journal of Obstetrics and Gynaecology*, 1992, 32(3):256-262.
172. Nizard J et al. Fertility and pregnancy outcomes following hypogastric artery ligation for severe post-partum haemorrhage. *Human Reproduction*, 2003, 18(4):844-848.
173. O'Leary JA. Uterine artery ligation in the control of postcaesarean hemorrhage. *Journal of Reproductive Medicine*, 1995, 40(3):189-193.
174. Papp Z et al. Hypogastric artery ligation for intractable pelvic hemorrhage. *International Journal of Gynaecology and Obstetrics*, 2006, 92(1):27-31.
175. Papp Z et al. [Bilateral hypogastric artery ligation for control of pelvic hemorrhage, reduction of blood flow and preservation of reproductive potential. Experience with 117 cases] *Orvosi hetilap*, 2005, 146(24):1279-1285.
176. Philippe HJ, d'Oreye D, Lewin D. Vaginal ligation of uterine arteries during postpartum hemorrhage. *International Journal of Gynecology and Obstetrics*, 1997, 56(3):267-270.
177. Pirard C et al. Uterine necrosis and sepsis after vascular embolization and surgical ligation in a patient with postpartum hemorrhage. *Fertility and Sterility*, 2002, 78(2):412-413.
178. Rezgui M et al. [Hypogastric artery ligation following obstetrical hemorrhage. Apropos of 1 case.] *La Tunisie médicale*, 1986, 64(3):261-263.
179. Roman H et al. Uterine devascularization and subsequent major intrauterine synechiae and ovarian failure. *Fertility and Sterility*, 2005, 83(3):755-757.
180. Saggara M, Glasser ST, Stone ML. Ligation of the internal iliac vessels in the control of postpartum hemorrhage: report of a case. *Obstetrics and Gynecology*, 1960, 15:698-701.
181. Shin RK, Stecker MM, Imbesi SG. Peripheral nerve ischaemia after internal iliac artery ligation. *Journal of Neurology, Neurosurgery, and Psychiatry*, 2001, 70(3):411-412.
182. Timoshenko LB, Zhitskii MO. [A case of puerperal death due to afibrinogenemia, unsuccessfully treated by ligation of the uterine vessels.] *Pediatriiâ akusherstvo i ginekologiiâ*, 1963, 58:53-54.
183. Tsurul'nikov MS. [Immediate and remote results of ligation of uterine vessels during postpartum hemorrhage.] *Akusherstvo i ginekologiiâ*, 1970, 46(7):59-61.

184. Tsurulnikov MS. [Ligation of the uterine vessels during obstetrical hemorrhages. Immediate and long-term results (author's transl.)] *Journal de Gynécologie, Obstétrique et Biologie de la Reproduction*, 1979, 8(8):751-753.
185. Tsvetkov TS et al. [Stepwise uterine devascularization in postpartum hemorrhages.] *Akusherstvo i ginekologija*, 2004, 43(1):9-5.
186. Yamashita T et al. [Case report of pregnancy and delivery after extraperitoneal ligation of the internal iliac artery.] *Sanfujinka no jissai*, 1970, 19(4):427-428.

#### Retained placenta

187. van Beekhuizen HJ et al. Sulprostone reduces the need for the manual removal of the placenta in patients with retained placenta: a randomized controlled trial. *American Journal of Obstetrics and Gynecology*, 2006, 194(2):446-450.
188. Carroli G, Bergel E. Umbilical vein injection for management of retained placenta. *Cochrane Database of Systematic Reviews*, 2001, Issue 4. Art. No.: CD001337.
189. The Release Trial: a randomised trial of umbilical vein oxytocin versus placebo for the treatment of retained placenta. <http://isrctn.org/ISRCTN13204258>.
190. Chongsomchai C, Lumbiganon P, Laopaiboon M. Prophylactic antibiotics for manual removal of retained placenta in vaginal birth. *Cochrane Database of Systematic Reviews*, 2006, Issue 2. Art. No.: CD004904.
191. Criscuolo JL et al. [The value of antibiotic prophylaxis during intrauterine procedures during vaginal delivery. A comparative study of 500 patients.] *Journal De Gynécologie, Obstétrique et Biologie de la Reproduction*, 1990, 19(7):909-918.
192. Small F, Hofmeyr GJ. Antibiotic prophylaxis for cesarean section. *Cochrane Database of Systematic Reviews*, 2002, Issue 3. Art. No.: CD000933.

#### Crystalloid use

193. Perel P, Roberts IG. Colloids versus crystalloids for fluid resuscitation in critically ill patients. *Cochrane Database of Systematic Reviews*, 2007, Issue 4. Art. No.: CD000567.

#### Guidelines

194. Lynch CB et al., ed. *Textbook of postpartum hemorrhage*. Kirkmahoe, Sapiens Publishing, 2006 ([www.sapienspublishing.com/medical-publications.php#1](http://www.sapienspublishing.com/medical-publications.php#1)).
195. Schuurmans N, MacKinnon C, Lane C, Etches D. *J Soc Obstet Gynaecol Can* 2000, 22(4):271-81.
196. François A, Courtois F. [Management of blood products in the event of postpartum hemorrhage.] *Journal de Gynécologie, Obstétrique et Biologie de la Reproduction*, 2004, 33(8 Suppl):4S1-4S136.
197. Argentina PPH management algorithm, 2008
198. *Guideline for the management of post-partum haemorrhage in the community* (version 2.1.1). Birmingham, Good Hope Hospital, NHS Trust, 2005.
199. Essential O&G Guidelines for district hospitals, South Africa, 1999
200. Guidelines for obstetric care at Coronation, Johannesburg and Natalspruit Hospitals. Johannesburg, University of the Witwatersrand, 1995.
201. Introducing WHO's sexual and reproductive health guidelines and tools into national programmes. Principles and processes of adaptation and implementation. Geneva, World Health Organization, 2007 (WHO/RHR/07.9).

## Annex 1. Scoping document with average scores

### Scoping results: Management of PPH due to uterine atony and retained placenta

Dear colleagues,

Please find for your review, the overall (averaged) responses to our questions and outcomes related to the management of:

- (1) postpartum haemorrhage due to uterine atony;
- (2) retained placenta following an uncomplicated delivery.

In separate analysis, items shaded were scored >7 by at least one category of respondents (nurse midwives, physicians, or non-clinicians).

Proposed questions		
<b>A. Blood loss estimation for the management of PPH</b>		
Score the importance of the question in the management of PPH on a scale from 1 to 9, where 1 = not important, 9 = critical	Should blood loss be routinely quantified during delivery for the appropriate management of PPH due to uterine atony, instead of visual estimation of blood loss?	6.06
<b>B. Medical interventions for the management of PPH</b>		
Assumptions		
<ul style="list-style-type: none"> <li>• Clinicians may perform several interventions simultaneously (i.e. uterine massage while medications are administered).</li> <li>• Clinicians are aware of standard contraindications of medications (although this will be reiterated in the final guideline and any derivative products).</li> </ul>		
For each drug listed score the importance of determining its efficacy as a uterotonic (with or without postpartum haemorrhage) on a scale from 1 to 9, where 1=not important, 9=critical	<b>Drug (in clinically accepted doses and routes of administration)</b>	<b>Need to determine efficacy</b>
	Carbetocin	5.98
	Carboprost (PGF <sub>2a</sub> )	4.85
	Ergometrine	5.43
	Misoprostol	6.92
	Oxytocin	5.30
	rFactor VIIa	5.95
	Syntometrine (fixed dose combination 5IU oxytocin + 0.5 mg ergometrine maleate)	5.20
	Sulprostone (PGE <sub>2</sub> )	5.20
Tranexamic acid	5.72	
For each question, please rate its importance in the management of PPH on a scale from 1 to 9, where 1=not important, 9=critical	Should certain combinations of medications be administered in the treatment of PPH?	6.92
	Should medications be administered in a sequential manner?	7.41
	Should use of one type of prostaglandin preclude use of other prostaglandins?	5.84
	Should the route of misoprostol administration vary if used as a first line (stand alone) treatment versus a second line treatment (in addition to, or sequentially with other medications)?	5.72

<b>C. Interventions for the management of PPH</b>			
For each procedure listed please score the relative importance of determining its efficacy in the management of PPH on a scale from 1 to 9, where 1=not important, 9=critical	Intervention	Procedure	Need to determine efficacy
		Non surgical	Uterine fundal massage
Bimanual uterine massage			6.75
Uterine packing			6.47
Uterine tamponade			6.90
External aortic compression			6.40
Anti-shock garments			6.78
Radiologic		Uterine artery embolization	6.44
Conservative surgical interventions		Compressive uterine sutures	6.90
		Uterine artery ligation	6.24
		Hypogastric (internal iliac) artery ligation	5.92
Definitive		Subtotal hysterectomy	5.39
	Total hysterectomy	5.53	
For each question please score its importance in the management of PPH on a scale from 1 to 9, where 1=not important 9=critical	Should non surgical interventions be attempted as a temporizing measure?		7.73
	Should invasive interventions be attempted sequentially?		7.60
	Should one surgical intervention be considered over others?		6.76
<b>D. Interventions for the management of retained placenta</b>			
For each question, please score it's relative importance in the management of retained placenta on a scale from 1 to 9, where 1=not important 9=critical	Should uterotonics be administered if retained placenta has been diagnosed (usually after 30 minutes)?		7.58
	Should intraumbilical vein injection of oxytocin/saline be administered after clinical diagnosis of retained placenta?		6.76
	Should a retained placenta be manually extracted after 30 minutes?		6.92
	Should antibiotics be routinely administered following manual extraction of a retained placenta?		7.33
<b>E. The role of health systems and institutions in the management of PPH due to uterine atony</b>			
For each question please score it's relative importance in the management of PPH on a scale from 1 to 9, where 1=not important 9=critical	Should each health system/institution have a formal protocol for the management of PPH?		8.51
	Should only physicians prescribe/administer uterotonics?		4.17
	Should only physicians perform interventions (non-surgical and surgical)?		5.49
	Should each facility have a formal protocol for the referral of patients?		8.27
	Should specific training courses with simulation of the management of PPH be offered to staff attending deliveries for the appropriate management of PPH, instead of routine curricula training?		7.93

Proposed outcomes			
			Importance
Please score the importance of each individual outcome in the management of PPH, on a scale from 1 to 9, where 1=not important 9=critical	Measurement and magnitude of blood loss	Accuracy in blood loss assessment	6.68
		Mean blood loss	5.70
		An additional blood loss $\geq 500$ ml (following initial PPH diagnosis)	7.17
		An additional blood loss $\geq 1000$ ml (following initial PPH diagnosis)	7.76
Please do not attempt to rank the outcomes		Postpartum anaemia (Hgb <11.0 g/dl)	6.49
		Blood transfusion	7.25
	Need for continued treatment	Additional uterotonics	7.44
	PPH management often involves a step-wise progression, so that need for one procedure may be seen as an outcome of another	Invasive nonsurgical treatment (uterine packing, bimanual uterine massage, tamponade)	7.21
		Surgical treatment (arterial ligation, compressive uterine sutures)	7.57
		Additional nonsurgical interventions (external aortic compression and compression garments)	6.82
		Arterial embolization	6.61
		Hysterectomy for PPH	7.69
	Adverse outcomes	Nausea, vomiting or shivering	5.48
		Maternal temperature greater than 38°C	5.92
		Maternal temperature greater than 40°C	7.54
		Delayed initiation of breastfeeding	5.68
		Prolonged hospitalization	6.70
		Procedure related complications	7.26
		Infection	7.48
		Severe morbidity (including coagulopathy, organ failure and ICU admission)	8.60
	Systems	Maternal transfer	7.33
		Reduction of time from decision making to implementation	8.20
		Availability of drugs and treatment	8.57

## Annex 2. Search strategy

The search strategy aimed to identify references dealing with the treatment of PPH. No limits were placed on the search regarding type of study, language or time frame.

In November 2007, the Cochrane library, Pubmed, Embase, and Lilacs were searched using the following terms:

- oxytocin
- ergometrine
- syntometrine
- misoprostol
- carboprost
- sulprostone
- factor VIIa
- tranexamic acid
- carbetocin
- bimanual or manual
- massage
- packing
- tamponade
- balloon
- catheter
- Bakri or Blakemore or Foley or condom
- compressive or compression or B-Lynch
- (arterial or vessel or vascular or artery or arteries) and ligation
- anti shock garments
- postpartum or post partum
- hemorrhage or haemorrhage or bleeding.

## Annex 3. GRADE methodology

The Grading of Recommendations Assessment, Development and Evaluation (short GRADE) Working Group began in the year 2000 as an informal collaboration of people with an interest in addressing the shortcomings of present grading systems in health care. The working group has developed a common, sensible and transparent approach to grading quality of evidence and strength of recommendations. Critical elements of using the GRADE system is described below. More information on GRADE methodology is presented at the web site <http://www.gradeworkinggroup.org/index.htm>.

**Table 1.** GRADE quality assessment criteria

Quality of evidence	Study design	Lower if *	Higher if *
High	Randomized trial	Study quality:	Strong association:
Moderate		Serious limitations: -1	Strong, no plausible confounders, consistent and direct evidence**: +1
		Very serious limitations: -2	Very strong, no major threats to validity and direct evidence***: +2
Low	Observational study	Important inconsistency: -1	Evidence of a dose-response gradient: +1
Very low	Any other evidence	Directness:	All plausible confounders would have reduced the effect: +1
		Some uncertainty: -1	
		Major uncertainty: -2	
		Sparse data: -1	
		High probability of reporting bias: -1	

\* Move up or down the indicated number of grades.

\*\* A statistically significant relative risk >2 (or <0.5), based on consistent evidence from two or more observational studies, with no plausible confounders.

\*\*\* A statistically significant relative risk >5 (or <0.2) based on direct evidence with no major threats to validity.

### Checklist for developing and grading recommendations

- Define the population, intervention and alternative, and the relevant outcomes.
- Summarize the relevant evidence (relying on systematic reviews).
- If reports of randomized trials are available, start by assuming high quality. If reports of well-done observational studies are available, assume low quality. Then check for:
  - serious methodological limitations (lack of blinding, concealment, high loss to follow-up, stopped early);
  - indirectness in population, intervention, or outcome (use of surrogates);
  - inconsistency in results;
  - imprecision in estimates.
- If there are limitations, downgrade RCTs from high to moderate, low or very low and observational studies to very low.
- If no randomized trials are available but well-done observational studies are available (including indirectly relevant trials and well-done observational studies), start by assuming low quality. Then check:
  - for large or very large treatment effect;
  - whether all plausible confounders would diminish effect of intervention;
  - for dose-response gradient.

- Grade up to moderate or even high, depending on special strengths.
- Studies starting at very low are not upgraded. Observational studies with limitations are not upgraded. Only observational studies with no threats to validity can be upgraded.
- Decide on best estimates of benefits, harms, burden and costs for relevant populations.
- Decide on whether the overall benefits are worth the potential harms, burden and costs for the relevant population and decide how clear and precise this balance is.

### Strength of recommendations

The strength of a recommendation reflects the degree of confidence that the desirable effects outweigh the undesirable effects. Desirable effects can include beneficial health outcomes, lower burden and cost savings. Undesirable effects can include harms, higher burden and extra costs. Burdens are the demands of adhering to a recommendation that patients or caregivers (e.g. family) may find onerous, such as having to undergo more frequent tests or requiring a longer time to recover.

Although the degree of confidence is actually a continuum, two categories are used: **strong** and **weak**.

A **strong recommendation** is one for which the group is confident that the desirable effects of adherence outweigh the undesirable effects.

A **weak recommendation** is one for which the group concludes that the desirable effects of adherence probably outweigh the undesirable effects, but is not confident about these trade-offs. Reasons for not being confident may include:

- absence of high quality evidence;
- presence of imprecise estimates of benefits or harms;
- uncertainty or variation in how different individuals value the outcomes;
- small benefits;
- the benefits may not be worth the costs (including the costs of implementing the recommendation).

Despite the lack of a precise threshold for going from a strong to a weak recommendation, the presence of important concerns about one or more of the above factors make a weak recommendation more likely. Groups should consider all of these factors and make the reasons for their judgements explicit.

Recommendations should specify the perspective that is taken (e.g. individual patient, health care system or society) and which outcomes were considered (including costs).

### Examples of implications of a strong recommendation are:

- **For patients:** Most patients would want the recommended course of action and only a small proportion would not.
- **For clinicians:** Most patients should receive the recommended course of action. Adherence to this recommendation is a reasonable measure of good quality care.
- **For policy-makers:** The recommendation can be adapted as a policy in most situations. Quality initiatives could use this recommendation to measure variations in quality.

### Examples of implications of a weak recommendation are:

- **For patients:** The majority of patients would want the recommended course of action, but many would not.
- **For clinicians:** Be prepared to help patients to make a decision that is consistent with their own values.
- **For policy-makers:** There is a need for substantial debate and involvement of stakeholders.

**Table 2.** Deciding on strength of a recommendation

Issue	Recommended process
<b>Quality of evidence</b>	
1. <b>Quality of evidence</b>	Strong recommendations usually require higher quality evidence for all the critical outcomes. The lower the quality of evidence, the less likely is a strong recommendation.
<b>Balance of benefits and harm</b>	
2. <b>Relative importance of the outcomes</b> a. benefits of therapy b. harm of treatment c. burdens of therapy	Seek evidence about the relative and actual values that patients place on outcomes (critical; important but not critical; not important). Seek evidence about variability in preferences and values among patients and other stakeholders. The relative importance of the outcomes should be included in the considerations before recommendations are made. If values and preferences vary widely, a strong recommendation becomes less likely.
3. <b>Baseline risks of outcomes</b> a. benefits of therapy b. harm of treatments c. burdens of therapy	Consider the baseline risk for an outcome. Is the baseline risk going to make a difference? If yes, then consider making separate recommendations for different populations.  The higher the baseline risk, the higher the magnitude of potential benefit and the higher the likelihood of a strong recommendation.
4. <b>Magnitude of relative risk</b> a. benefits (reduction in RR) b. harms (increase in RR) c. burden	Consider the relative magnitude of the net effect. Large relative effects will lead to a higher likelihood of a strong recommendation if the balance of benefit, harms and burden go in the same direction. If they go in opposite directions and the relative magnitude of effects is large (large benefits coming with large risk of adverse effects), the recommendation is more likely to be weak.
5. <b>Absolute magnitude of the effect</b> a. benefits b. harms c. burden	Large absolute effects are more likely to lead to strong recommendation.
6. <b>Precision of the estimates of the effects</b> a. benefits of therapy b. harms of treatments c. burdens of therapy	The greater the precision the more likely the recommendation is strong.
7. <b>Factors that modify effects in specific settings/</b> <b>Local factors that may affect translation of the evidence into practice</b>	The more similar the setting and patients for which one is making a recommendation to the setting and patients generating the evidence, the more likely the recommendation is strong.
8. <b>Costs</b>	Consider that important benefits should come at a reasonable cost. The higher the incremental cost, all else being equal, the less likely that the recommendation in favour of an intervention is strong.

## Annex 4. List of participants

**Dr Edgardo Abalos**

Centro Rosarino de Estudios Perinatales (CREP)  
Rosario, Santa Fé  
Argentina

**Dr Hany Abdel Aleem**

Professor of Obstetrics and Gynecology  
Faculty of Medicine, Assiut University  
Department of Obstetrics and Gynecology,  
Assiut University Hospital  
Assiut  
Egypt

**Ms Deborah Armbruster**

PATH  
Washington, DC  
USA

**Ms Jennifer Blum**

Gynuity Health Projects  
New York, NY  
USA

**Dr Michel Boulvain**

Maternité  
Hôpitaux Universitaires de Genève  
Geneva  
Switzerland

**Dr Guilherme Cecatti**

Obstetrics Unit  
Department of Obstetrics and Gynecology  
School of Medical Sciences  
State University of Campinas  
Campinas, São Paulo  
Brazil

**Dr Doris Chou**

Bethesda, MD  
USA

**Richard J. Derman**

Chair, Department of Obstetrics and Gynecology  
Christiana Care Health Services  
Director, Center for Women and Children's Health Research  
Clinical Professor, Department Obstetrics and Gynecology  
Jefferson Medical College  
Newark, Delaware  
USA

**Dr Diana Elbourne**

Professor of Health Care Evaluation  
Medical Statistics Unit  
London School of Hygiene and Tropical Medicine  
London  
United Kingdom

**Ms Gill Gyte**

Research Associate  
Cochrane Pregnancy and Childbirth Group  
University of Liverpool  
Liverpool Women's Hospital NHS Trust  
Liverpool  
United Kingdom

**Dr Justus Hofmeyr**

Director  
University of the Witwatersrand/  
University of Fort Hare/Eastern Cape Department of Health  
Effective Care Research Unit  
East London, Eastern Cape  
South Africa

**Dr André B. Lalonde**

Executive Vice-President  
The Society of Obstetricians and Gynaecologists of Canada  
Ottawa  
Canada

**Dr Pisake Lumbiganon**

Convenor, Thai Cochrane Network  
Faculty of Medicine  
Khon Kaen University  
Khon Kaen  
Thailand

**Dr Enrique Oyarzun**

Chairman, Department of Obstetrics and Gynecology  
Faculty of Medicine  
Pontificia Universidad Católica de Chile  
Santiago  
Chile

**Dr Zahida Qureshi**

Obstetrician/Gynaecologist  
Senior Lecturer  
Department of Obstetrics/Gynaecology  
University of Nairobi  
Kenya

**Professor Surasak Taneepanichskul**

Dean, College of Public Health Sciences  
Chulalongkorn University  
Bangkok  
Thailand

**Dr Tran Son Thach**

Director  
Hung Vuong Hospital  
Ho Chi Minh City  
Viet Nam

**Dr Juan Carlos Vazquez**

Instituto Nacional de Endocrinología  
Hospital "Cmdte. Fajardo"  
Havana  
Cuba

**Dr Jean José Wolomby**

Department of Gynecology and Obstetrics  
Cliniques Universitaires de Kinshasa  
Kinshasa  
Democratic Republic of Congo

## OBSERVERS

**Ms Mary Ellen Stanton**  
Senior Reproductive Health Advisor  
Center for Population, Health and Nutrition  
United States Agency for International Development  
Washington, DC  
USA

**Dr Beverly Winikoff**  
Gynuity Health Projects  
New York, NY  
USA

## INVITED BUT UNABLE TO ATTEND

**Dr Zarko Alfirovic**  
Senior Lecturer  
Department of Obstetrics and Gynaecology  
Liverpool Women's Hospital  
Liverpool  
United Kingdom

**Dr Hassan Ba'Aqeel**  
King Khalid National Guard Hospital  
Department of Obstetrics and Gynecology  
Jeddah  
Saudi Arabia

**Dr Eckhart Buchmann**  
Killarney  
Johannesburg  
South Africa

**Dr France Donnay**  
Senior Program Officer, Maternal Health  
Integrated Health Solutions Development  
Bill & Melinda Gates Foundation

**Dr Jim Neilson**  
Dean, NIHR Faculty Trainees  
Professor of Obstetrics and Gynaecology  
School of Reproductive and Developmental Medicine  
University of Liverpool;  
Joint Co-ordinating Editor  
Cochrane Pregnancy & Childbirth Group  
University Department  
Liverpool Women's Hospital  
Liverpool  
United Kingdom

**Dr Lakshmi Seshadri**  
Professor, Department of Obstetrics and Gynaecology  
Christian Medical College Hospital  
Vellore  
India

**Dr Lynn Sibley**  
Associate Professor  
Lillian Carter Center for International Nursing  
Director, Center for Research on Maternal and Newborn Survival  
Nell Hodgson Woodruff School of Nursing  
Emory University  
Atlanta, GA  
USA

**Dr Martin Whittle**  
King's Court  
London  
United Kingdom

**Professor Qian Xu**  
Department of Maternal and Child Health  
School of Public Health  
Fudan University  
Shanghai  
China

## WHO REGIONAL OFFICE

**Dr Akjemał Magtymova**  
(unable to attend)  
Reproductive Health & Research  
WHO Regional Office for South-East Asia  
World Health House  
Indraprastha Estate  
New Delhi  
India

## WHO SECRETARIAT

**Dr A. Metin Gülmezoglu**  
Scientist  
Reproductive Health and Research  
Technical Cooperation with Countries

**Dr Suzanne Hill**  
Scientist  
Medicines Policy, Essential drugs and Traditional Medicine  
Policy, Access and Rational Use

**Dr Matthews Mathai**  
Medical Officer  
Making Pregnancy Safer  
Norms and Technical Support

**Dr Mario Merialdi**  
Coordinator  
Reproductive Health and Research  
Maternal and Perinatal Health

**Dr João Paulo Souza**  
Medical Officer  
Reproductive Health and Research  
Technical Cooperation with Countries